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Peritoneal dissemination is the primary metastatic route for ovarian cancer, which is generally 
diagnosed at advanced stages and has a high mortality rate. Ovarian cancer is often 
accompanied by the accumulation of ascitic fluid, which contains a high concentration of 
cytokines, chemokines, exosomes and suspended cells. During peritoneal metastasis, cancer 
cells detach from the primary tumour, disseminate through the peritoneal fluid and attach to the 
mesothelial cell (MC) monolayer that lines the peritoneal cavity. Then, they invade the 
submesothelial compact zone where carcinoma-associated fibroblasts (CAFs) accumulate. 
CAFs represent an important population in the tumour microenvironment, may derive from 
different sources, and participate in several stages of tumour progression, including cancer cell 
migration/invasion and metastasis. This work shows that in peritoneal metastasis, a sizeable 
subpopulation of CAFs originates from MCs through a mesothelial-to-mesenchymal transition 
(MMT) induced by cancer cells. Additionally, immunofluorescence staining and RT-PCR 
analysis indicated that MCs in malignant ascitic fluid (AFMCs) are undergoing MMT; and 
RNA-seq analysis confirmed a large proportion of the differentially regulated pathways were 
associated primarily with MMT. The MMT in AFMCs is shown to be taking place via a TGF-
1 Smad-dependent pathway, and the mesenchymal conversion in these cells favoured tumour 
growth in a subcutaneous xenograft mouse model. In peritoneal biopsies of ovarian cancer 
patients, nuclear pSmad3-positive MC-derived CAFs surrounded the micrometastases. 
Surprisingly, in cancer cells, pSmad3 expression remained cytoplasmic. This differential 
localization was confirmed in vitro upon TGF-1 stimulation, suggesting that, despite 
producing large amounts of TGF-1, the Smad-dependent pathway is truncated in ovarian 
cancer cells, requiring MCs for environment transformation. Consequently, the impact of MMT 
in tumour progression was studied using an in vivo bioluminescence imaging mouse model for 
peritoneal dissemination. By overexpressing or blocking TGF-1 in the peritoneum, tumour 
growth was favoured or reduced, respectively. Also, knockdown of Smad3 in the peritoneum 
resulted in reduced tumour progression, confirming the Smad-dependent pathway is relevant in 
peritoneal metastasis. These results suggest that CAFs derived from MCs through a MMT 
create a suitable metastatic niche for ovarian cancer progression. This work suggests the 
peritoneal environment could constitute an alternative target in the treatment of ovarian cancer 
metastasis, by strategically modulating the MMT with known pharmacological agents.*
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El cáncer de ovario se detecta generalmente en estadios avanzados, tiene una alta tasa de 
mortalidad, y metastatiza principalmente por la ruta peritoneal. Suele ir acompañado de la 
acumulación de líquido ascítico, que contiene una alta concentración de citoquinas, 
quimioquinas, exosomas y células en suspensión. Durante la metástasis peritoneal, las células 
cancerosas se desprenden del tumor primario, diseminan a través del líquido peritoneal y se 
adhieren a la monocapa de células mesoteliales (MCs) que recubre la cavidad peritoneal. A 
continuación, invaden la zona submesotelial, donde se acumulan los fibroblastos asociados a 
cáncer (CAFs). Los CAFs son una población celular importante en el microambiente tumoral, 
derivan de varios tipos celulares, y participan en varias etapas de la progresión tumoral, como la 
migración/invasión y metástasis. Este trabajo muestra que, en la metástasis peritoneal, una parte 
considerable de los CAFs proviene de las MCs mediante una transición mesotelio-mesénquima 
(MMT) inducida por las células cancerosas. Se observó mediante inmunofluorescencia, RT-
PCR y RNA-seq que las MCs del líquido ascítico maligno (AFMCs) han sufrido una MMT. 
Esta MMT en AFMCs se lleva a cabo mediante la ruta Smad-dependiente de TGF-1, y la 
conversión mesenquimal de estas células favoreció el crecimiento tumoral en un modelo de 
xenoinjerto subcutáneo en ratón. En biopsias peritoneales de cáncer de ovario, los CAFs 
derivados de MCs rodeaban las micrometástasis y expresaban pSmad3 nuclear. 
Sorprendentemente, en las células cancerosas, la expresión de pSmad3 se limitaba al 
citpolasma. Esta localización diferencial se confirmó in vitro tras estimular con TGF-1 y 
sugiere que, a pesar de producir grandes cantidades de TGF-1, la ruta Smad-dependiente está 
truncada en las células de cáncer de ovario, que requieren a las MCs para transformar el 
ambiente. Por ello, se estudió el impacto de la MMT en la progresión tumoral intraperitoneal. 
La sobreexpresión o el bloqueo de TGF-1 en el peritoneo favoreció o disminuyó el 
crecimiento tumoral, respectivamente. El knockdown de Smad3 en el peritoneo resultó en una 
progresión tumoral reducida, confirmando el papel de la vía Smad-dependiente en la metástasis 
peritoneal. Esto sugiere que los CAFs derivados de MCs mediante una MMT crean un nicho 
metastático favorable para la progresión del cáncer de ovario. El presente trabajo sugiere que el 
ambiente peritoneal podría representar una diana terapéutica alternativa en el tratamiento de la 
metástasis del cáncer de ovario, modulando estratégicamente la MMT. 
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AFMCs Ascitic Fluid-derived Mesothelial Cells 
α-SMA α -smooth muscle actin 
BCEF-AM 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl 
ester BMP-7 Bone morphogenetic protein 7 
CA125/MUC16 Cancer antigen 125/mucin 16 
CAFs Carcinoma-associated fibroblasts 
CAV-1 Caveolin 1 
DAB 3,3′-diaminobenzidine 
DAPI 4,6-diamidino-2-phenylindole  
DMEM Dulbecco's modified eagle medium 
DMSO Dimethyl sulfoxide 
ECL Enhanced chemiluminiscence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial-to-Mesenchymal Transition 
EndMT Endothelial-to-Mesenchymal Transition 
ERK Extracellular signal-Regulated Kinase 
ET-1 Endothelin 1 
FAP Fibroblast activation protein 
FGF-2 Fibroblast growth factor 2 
FBS Fetal bovine serum 
FSP1 Fibroblast specific protein 1 
FSP1 Fibroblast-specific protein 1 
H&E Haematoxilyn and Eosin 
HGF Hepatocyte growth factor 
HGFR Hepatocyte growth factor receptor 
HIPEC Hyperthermic intraperitoneal chemotheraphy 
HPMCs Human peritoneal mesothelial cells 
ICAM-1 Intercellular adhesion molecule 1 
IL-10 Interleukin 10 
IL-1β Interleukin 1 beta  
IL-6 Interleukin 6 
IL-8 Interleukin 8 
ILK Integrin-linked kinase 
JNK C-Jun N-terminal Kinase 
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LB Lysogeny broth 
MAPK Mitogen-activated protein kinase 
MCs Mesothelial cells 
miRNA Micro RNA 
MMP-2 Matrix metalloprotease 2 
MMP-9 Matrix metalloprotease 9 
MMT Mesothelial-to-Mesenchymal Transition 
NF-κB Nuclear Factor-kappa B 
NRP1 Neuropilin 1 
PAI-1 Plasminogen activator inhibitor 1 
PBN Α-phenyl-N-tert-butyl-nitrone  
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGF Plateled-derived growth factor 
PI3K/Akt Phosphoinositide 3-kinase/protein kinase b 
PPAR Peroxisome proliferator-activated receptor 
qRT-PCR Quantitative real time polymerase chain reaction 
RIPA Radioimmunoprecipitation assay 
rMMT Reverse MMT 
RPMI Roswell Park Memorial Institute medium 
RXR Retinoid X receptor 
shRNA Small hairpin RNA 
SOC Super Optimal Broth with Catabolite repression 
T+I Transforming Growth Factor beta 1 + Interleukin-1 beta 
TAK-1 Transforming Growth Factor beta-Activated Kinase 1  
TBS Tris-buffered saline 
TGF-β1 Transforming Growth Factor beta 1  
TNF-α  Tumour Necrosis Factor α  
TSP1 Thrombospondin 1 
uPA Urokinase-type Plasminogen Activator 
VCAM-1 Vascular cell adhesion molecule 1 
VDR Vitamin D receptor 
VEGF Vascular endothelial growth factor 
VEGFR2 Vascular endothelial growth factor receptor 2 
WT1 Wilm's tumour 1 
ZO-1 Zona occludens 1 
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1. Peritoneal metastasis 
The majority of tumours are confined to the organ where they first originated and are 
usually treatable and curable with local therapy. However, several neoplasias are incurable due 
to processes that govern the ability of cells to disseminate and implant in distant locations. 
Although hematogenous and lymphatic dissemination are the most common routes for 
metastasis, tumours originating adjacent to the peritoneal cavity, such as ovarian or colorectal 
cancer, frequently disseminate via transcoelomic route to develop peritoneal metastases. Cancer 
cells detached from the primary tumour are transported by peritoneal fluid to subsequently 
spread locally, colonizing the peritoneum (Tan et al. 2006; de Cuba et al. 2012). This process is 
known as peritoneal metastasis and signifies that the disease is at advanced stage, is difficult to 
treat and, often, there is no prospect of cure. A common characteristic of abdominal cancers that 
progress with peritoneal metastasis is that they generally evolve very rapidly and correlate with 
poor prognosis. The peritoneal cavity is the site of metastases in up to 28% of recurrent 
endometrial cancers (Sohaib et al. 2007), 42% of colorectal cancers (Koppe et al. 2006), 40% of 
gastric cancers (Montori et al. 2014) and 70% of ovarian advanced cancers (Tan et al. 2006). 
Surgery is inefficient to render patients free of disease, resulting in low survival rates. This is in 
part due to the diffuse nature of peritoneal metastases, making them generally intractable to 
surgical resection. Nowadays, aggressive surgical tumour removal (tumour cytoreduction) 
coupled with hyperthermic intraperitoneal chemotherapy (HIPEC) represents the cornerstone of 
advanced abdominal oncologic surgery. The combination of both treatments seems to be 
encouraging and, in colorectal and gynecological cancers, provides 5-year survival rates of over 
40% and 45%, respectively (Glehen et al. 2006; Bakrin et al. 2014). However, these are 
complex therapies that require specialized technological facilities with highly qualified human 
resources, and the possibility of curing advanced stage intraperitoneal tumours still remains 
limited (Glockzin et al. 2009). Part of this problem derives from the fact that the pathogenesis of 
peritoneal carcinomatosis is not well understood. Therefore, to design new therapeutic 
Introduction!!!
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approaches it is necessary to improve our knowledge of the mechanisms implicated in tumour 
progression in the peritoneum. 
1.1. Ovarian cancer 
Ovarian cancer is the fifth leading cause of cancer-related deaths in women (Siegel et al. 
2016). The epithelial type is the most frequent (90% of cases) and, based on histopathology, can 
be divided into serous (most common), mucinous, endometrioid and other less common types, 
such as clear cell (Hennessy et al. 2009). Ovarian cancers are classified in 4 stages, I and II 
being early-stage, and III and IV advanced-stage. The high mortality rates are explained by the 
fact that, at diagnosis, 70% of women present an advanced stage, meaning that cancer cells have 
reached the peritoneal cavity (Tan et al. 2006; Hennessy et al. 2009; Lengyel 2010; Thibault et 
al. 2014). Long-term survival rates (>10 years) are dramatically different between early-stage 
(80-95%) and advanced-stage (10-30%) (Hennessy et al. 2009). In contrast to other types of 
cancer, ovarian preferentially metastasizes through the peritoneal cavity, and not 
hematogenously (Tan et al. 2006). 
2. The seed and soil theory in peritoneal metastasis 
Metastasis remains the major cause of death for cancer patients. Cancers that 
metastasize are generally more difficult to treat and have a worse prognosis than those that 
remain at the site of origin (Chambers et al. 2002). During peritoneal metastasis, cancer cells 
leave the primary tumour to colonize the secondary organ (peritoneum), where they develop 
into metastatic lesions. The peritoneum is a well-known metastatic site for several intra-
abdominal malignancies, such as ovarian, colon, gastric, pancreatic, endometrial and rectal 
cancer. However, the specific site of distant metastasis is not simply due to the intrinsic features 
of the primary tumour, its anatomic location or proximity to secondary sites but, rather, it 
involves interactions between tumour cells and the local microenvironment at the secondary 
site. Therefore, in the establishment of metastasis, the properties of the tumour are as important 
as the metastatic niche. In 1899, Stephen Paget suggested the “seed and soil” hypothesis to 
Introduction!!!
! 17!
explain how sites where metastases occur are defined not only by the tumour cell (“seed”) but 
also the microenvironment of the secondary metastatic site (“soil”). Accordingly, metastases are 
influenced by innumerable factors and complex cellular interactions between the seed and the 
soil (Mendoza and Khanna 2009; Mathot and Stenninger 2012). In the case of peritoneal 
carcinomatosis, the metastatic niche is composed of the surface of the peritoneum overlying the 
abdominal cavity. The organization of the peritoneum is simple: a single layer of mesothelial 
cells (MCs) lines a compact region that is composed of connective tissue with a few fibroblasts, 
mast cells, macrophages and blood vessels (Di Paolo and Sacchi 2000). The “seed and soil” 
mechanism could be especially relevant in peritoneal metastasis, since modification of the 
surrounding metastatic stroma may facilitate the processes of attaching to and invading through 
the peritoneal membrane. 
3. Carcinoma-associated fibroblasts in the peritoneum 
Currently, there is an increased understanding of the processes that govern the 
malignant transformation of cells. It is known that tumour development is mainly associated 
with the accumulation of multiple genetic and epigenetic alterations in cancer cells which pave 
the way for the transformation of a normal cell into a malignant cell (Hanahan and Weinberg 
2011). However, tumours are highly complex organs composed of different cell types. Cancer 
tissue consists of both tumour cells and stromal cells surrounded by an extensive extracellular 
matrix (ECM). The stromal component constitutes a large part of most solid tumours and 
includes multiple cell types like mesenchymal, vascular and immune cells that converge to 
support a tumourigenic niche. The development of the tumour microenvironment is triggered by 
stimulating molecules secreted by cancer cells that corrupt the adjacent normal tissue to create 
an “activated” stroma (Bhome et al. 2015). 
The peritoneal pre-metastatic niche is basically composed of MCs, fibroblasts, 
endothelial cells, adipocytes and immune cells, including macrophages. However, during 
peritoneal metastasis normal mesothelium is replaced by a strong stromal reaction 
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(desmoplasia) characterized by the accumulation of activated fibroblasts (myofibroblasts) 
(Kojima et al. 2014). The exacerbated accumulation of activated fibroblasts in the peritoneum 
has been previously described in other fibrotic disorders including peritoneal dialysis-induced 
fibrosis (Jimenez-Heffernan et al. 2004) and abdominal adhesions (Chegini 2008; Sandoval et 
al. 2016). In cancer stroma, carcinoma-associated fibroblasts (CAFs)—also called activated or 
reactive stromal fibroblasts—are prominent modifiers of tumour progression towards advanced 
stages, favouring proliferation, survival and invasion of cancer cells, and their presence is often 
associated with poor clinical prognosis for oncology patients (Shimoda et al. 2010; Polanska 
and Orimo 2013). CAFs share characteristics with myofibroblasts like the expression of alpha-
smooth muscle actin (α-SMA) (Desmoulière et al. 1993; Lazard et al. 1993; Desmoulière and 
Gabbiani 1994), fibroblast activation protein-alpha (FAP-α) (Calon et al. 2012; Wikberg et al. 
2013) and fibroblast-specific protein 1 (FSP1) (Strutz et al. 1995; Polanska and Orimo 2013). 
CAFs are capable of producing a wide array of cytokines, growth factors, proteases, and ECM 
components, thereby promoting inflammation, immunosuppression and ECM remodelling 
(Polanska and Orimo 2013). Additionally, CAFs have been widely implicated in promoting 
tumour angiogenesis, which is necessary for cancer survival and metastasis towards secondary 
organs (Bhowmick et al. 2004; Wels et al. 2008). 
3.1. Mesothelial cells as a possible source of carcinoma-associated fibroblasts 
An important effect of the tumour nesting into the peritoneal membrane is the 
exacerbated accumulation of CAFs (Kojima et al. 2014). However, the multiple origins of 
peritoneal CAFs are still debated today. It has been proposed that CAFs may derive from 
different sources depending on the surrounding tumour metastatic niche (Figure 1). 
Additionally, there is emerging evidence that the origin of CAFs may vary between cancer 
types and within different areas of individual tumours (Cirri and Chiarugi 2012). The activation 
of resident fibroblasts was considered the main origin of CAFs in the tumour microenvironment 
(Desmoulière et al. 2004). However, recent studies have revealed that bone marrow-derived 
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stem cells (fibrocytes) (Ishii et al. 2003; Direkze et al. 2004; Kidd et al. 2012) and adipocytes 
(Jotzu et al. 2010; Bochet et al. 2013) differentiate into CAFs and are integrated into the tumour 
stroma. Pericytes have also been described to convert into myofibroblasts at injury sites, 
representing another possible source of CAFs (Göritz et al. 2011; Dulauroy et al. 2012). Cancer 
cells of epithelial origin can undergo an epithelial-to-mesenchymal transition to acquire 
myofibroblast properties, although their contribution to the CAF population is considered to be 
small (Kalluri and Zeisberg 2006; Radisky et al. 2007; Cirri and Chiarugi 2012). In addition, it 
has been shown that endothelial cells, through an endothelial-to-mesenchymal transition, may 
also be a source of CAFs (Potenta et al. 2008; Zeisberg et al. 2008). Moreover, MCs are 
considered an important source of activated fibroblasts in pathologies that present fibrosis. The 
presence of MCs converted into myofibroblasts through mesothelial-to-mesenchymal transition 
(MMT) was first described in the peritoneum of peritoneal dialysis patients (Yanez-Mo et al. 
2003), and has recently been implicated in the formation of post-surgical adhesions (Sandoval et 
al. 2016). Emerging evidence has subsequently revealed that MMT is an important event in 
numerous fibrogenic disorders such as idiopathic lung fibrosis (Karki et al. 2014), liver 
fibrogenesis (Li et al. 2013) and myocardial infarction scars (Deb and Ubil 2014; Ruiz-Villalba 
et al. 2015). Interestingly, FAP-positive mesothelium in gastric cancer patients has been 
associated with advanced stage disease, peritoneal dissemination and poor survival (Miao et al. 
2014). However, the possible conversion of MCs into CAFs during peritoneal carcinomatosis 
via a MMT has not yet been studied. 
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Figure 1. Multiple origins of CAFs. 
CAFs may derive from at least six different sources through various mechanisms: phenotypic 
activation from interstitial fibroblasts; differentiation from adipocytes and vascular pericytes; 
recruitment from circulating fibrocytes; capillary endothelial-mesenchymal transition (EndMT); 
and epithelial-mesenchymal transition (EMT). The relative contribution of each source to the 
CAF pool in peritoneal metastasis has not yet been elucidated. In this context, the possible 
conversion of MCs into CAFs via a MMT has not yet been studied. Modified from M López-
Cabrera, Advances in Medicine 2014. 
4. Mesothelial-to-mesenchymal transition and promoting stimuli in peritoneal 
metastasis 
The MMT is a complex and stepwise epithelial-to-mesenchymal transition (EMT)-like 
process that involves alterations in the cellular architecture and a deep molecular 
reprogramming (Figure 2), where MCs lose their epithelial characteristics and acquire a 
myofibroblastic phenotype (Yanez-Mo et al. 2003; López-Cabrera 2014). The process starts 
with the dissociation of intercellular junctions, due to downregulation of intercellular adhesion 
molecules, and with the loss of microvilli and apico-basal polarity. Then, cells adopt a front-
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back polarity, acquire α-SMA expression and increase their migratory capacity. In the last 
stages of the MMT, the cells acquire the capacity to degrade the basement membrane and to 
invade the fibrotic compact zone (Kalluri and Weinberg 2009). During the end stages of 
myofibroblast conversion, MCs are able to produce a large amount of extracellular matrix 
components and synthesize a wide range of inflammatory, profibrotic and angiogenic factors 
that may contribute to structural and functional changes in the peritoneal membrane (Margetts 
and Bonniaud 2003; Yanez-Mo et al. 2003; Aguilera et al. 2005; Aroeira et al. 2007; Devuyst et 
al. 2010; López-Cabrera 2014). 
!
Figure 2. Schematic illustration of the key events during MMT. 
Mesothelial to mesenchymal transition (MMT) occurs when mesothelial cells lose their 
epithelial-like characteristics, including dissolution of cell-cell junctions (tight junctions, 
adherens junctions and desmosomes) and loss of apico-basal polarity. Then, cells acquire a 
mesenchymal phenotype, characterized by actin reorganization and stress fiber formation, and 
the ability to migrate and invade the stroma. The diagram shows four essential key steps for the 
completion of an entire MMT, the most commonly used mesothelial and mesenchymal markers, 
and the molecules and signal transduction pathways that act either as inducers or modulators of 
the MMT process. Modified from M López-Cabrera, Advances in Medicine 2014. 
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In the context of peritoneal metastasis, the promoting stimuli able to induce the 
mesenchymal conversion of MCs are not still completely characterized. On this note, an 
important characteristic of patients that develop peritoneal carcinomatosis is the presence of 
ascites, the pathological accumulation of fluid in the peritoneal cavity (Figure 3). Ascites is the 
combined result of lymphatic obstruction, the effect of soluble factors, and an increase in 
peritoneal fluid production and in vascular permeability (Adam and Adam 2004). In this 
context, ovarian cancer can account for up to 47% of malignant ascites, followed by other 
gastrointestinal cancers; all of them correlate with poor survival, gastrointestinal tumours being 
the most severe (Parsons et al. 1996; Ayantunde and Parsons 2007; Ayhan et al. 2007). 
Malignant ascitic fluid is composed of cytokines, chemokines, growth factors, exosomes and 
suspended cells that vary in proportion between patients: leukocytes, MCs, macrophages, 
tumour cells and plasma cells (Sheid 1992; Milliken et al. 2002; Graves et al. 2004; Choi et al. 
2011; Matte et al. 2012).  
Exosomes are vesicular portions of membrane material, which were initially described 
by Thery et al. (Théry et al. 2002) and serve as vehicles that transfer proteins, as well as RNA 
(mRNA and miRNA), between cells. Tumours are able to release exosomes, and these have 
been found in malignant ascites from patients with ovarian and gastrointestinal cancers (Choi et 
al. 2011; Peng et al. 2011; Cappellesso et al. 2014; Tokuhisa et al. 2015). While the precise 
mechanism of communication between cancer and MCs in the peritoneum remains unclear, 
there is growing evidence that exosomes may serve as prognostic/diagnostic indicators of 
peritoneal dissemination. Regarding this idea, exosomes derived from colorectal cancer ascites 
contain proteins that may promote tumour progression via angiogenesis, disruption of epithelial 
cell polarity, immune modulation, tumour growth and invasion (Choi et al. 2011). 
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Figure 3. Malignant ascites and modification of the peritoneal membrane. 
The peritoneal membrane (outlined in blue) lines the abdominal wall and visceral organs. The 
structure of a normal peritoneal membrane (left) consists of a monolayer of mesothelial cells, 
bound by tight junctions, that line the stroma, containing extracellular matrix, fibroblasts and 
capillaries. In normal conditions, the oncotic pressure is high at the endothelial layer and low at 
the mesothelial layer, limiting capillary fluid filtration and allowing the reabsorption of water 
into the capillaries. Patients with tumours in the abdominal cavity (right) have an increased 
number of permeable vessels and filtration surface for fluid. Malignant ascites contains a high 
protein concentration, accumulates cytokines and chemokines, and has a reduced lymphatic 
flow. This translates into a lower peritoneal oncotic pressure, and a flow of fluid into the 
peritoneal cavity, leading to ascites. Modified from E. Kipps et al., Nat Rev Cancer 2013. 
 On this note, ovarian cancer exosomes administered to mice prior to tumour cell 
injection have been shown to induce a more aggressive disease and to increase tumour growth 
(Vaksman et al. 2014). Of the miRNAs contained in exosomes, miR-21, known for its pro-
oncogenic activity (Selcuklu et al. 2009), is present in both ovarian (Cappellesso et al. 2014) 
and gastric (Tokuhisa et al. 2015) cancer ascites.  Expression of miR-21 in exosomes is 
associated with pathways related to transforming growth factor β (TGF-β) signalling, ECM-
Introduction!!!
!
receptor interaction, mesothelial clearance and worse prognosis/diagnostic value; thus, it may 
provide a novel approach for early diagnosis of peritoneal dissemination (Vaksman et al. 2014; 
Tokuhisa et al. 2015). Also, Vaksman et al. concluded that the effect of exosomes is mainly 
exerted on MCs, rather than on tumour cells, and higher miRNA levels are associated with poor 
survival (Vaksman et al. 2014). These data suggest that exosomes may play a role in modifying 
the metastatic niche to favour peritoneal dissemination.  
Also present in the malignant ascitic fluid is a high concentration of cytokines and 
growth factors, including TGF-β1, tumour necrosis factor-alpha (TNF-α), vascular endothelial 
growth factor (VEGF), hepatocyte growth factor (HGF), interleukin-1 beta (IL-1β), interleukin-
6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) (Moradi et al. 1993; Nash et al. 1998; 
Sowter et al. 1999; Santin et al. 2001; Manenti et al. 2003; Stadlmann et al. 2005; Mustea et al. 
2006; Giuntoli et al. 2009; Matte et al. 2014a). Interestingly, many of these soluble mediators, 
such as TNF-α, IL-6, TGF-β1 and IL-1β, have important pro-inflammatory roles in the 
peritoneal environment and, as a consequence, have been widely implicated in fibrosis by 
stimulating fibroblast proliferation (Masunaga et al. 2003; Fredj et al. 2005), ECM component 
deposition, and MMT induction (Demir et al. 2005; López-Cabrera 2014). Therefore, it is 
tempting to speculate that, in peritoneal metastasis, diverse cytokines could be contributing to 
the modification of the mesothelial surface in order to initiate tumour implantation (Freedman et 
al. 2004; Matte et al. 2014a; Kolomeyevskaya et al. 2015). To this effect, elevated IL-6 and 
TNF-α in ascites of patients in late stages of ovarian cancer are considered independent 
predictors of poor survival (Lane et al. 2011; Kolomeyevskaya et al. 2015). 
Among the growth factors accumulated in ascites, HGF has recently been implicated in 
the implantation of endometrial cells (Ono et al. 2015) and ovarian cancer cells (Nakamura et al. 
2015) in the peritoneum via a MMT. 
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4.1. TGF-β signalling pathway  
 The TGF-β superfamily of proteins includes, among others, TGF-βs, activins, and bone 
morphogenic proteins (BMPs), and is implicated in a wide range of cellular processes, such as 
proliferation, differentiation and apoptosis (Shi and Massagué 2003; Feng and Derynck 2005). 
TGF-β is a master molecule produced by many cell types, presents both anti- and pro-tumoural 
effects, and is found in high concentration in malignant ascitic fluid (Santin et al. 2001; 
Wakefield and Roberts 2002; Massagué and Gomis 2006). Tumour cells may evade the tumour 
suppressor activity of TGF-β while, at the same time, while responding to the tumour-
promoting signals. TGF-β also has a effect on the stroma, and has been reported to increase the 
efficiency of organ colonization by tumour cells (Calon et al. 2012). A large proportion of 
tumours, including colorectal and ovarian cancer, display mutational inactivation of the TGF-β 
pathway yet some, paradoxically, are also characterized by elevated TGF-β production 
(Wakefield and Roberts 2002; Massagué and Gomis 2006; Yamamura et al. 2011; Calon et al. 
2014). Moreover, TGF-β1 is a prototypical inducer of the myofibroblast conversion of MCs via 
MMT (Yanez-Mo et al. 2003; Loureiro et al. 2011). Additionally, the myofibroblast conversion 
of fibroblasts via TGF-β1 has been shown to take place in a Smad-dependent manner (Evans et 
al. 2003). On this note, in the EMT induced by TGF-β, Smad3 plays a key role in fibrosis, pro- 
and anti-tumoural effects and β1 integrin expression (Roberts et al. 2006; Yeh et al. 2010). Miao 
et al. demonstrated that gastric cancer cells expressing high levels of TGF-β1 promote both 
downregulation of E-cadherin and upregulation of α-SMA in the mesothelium (Miao et al. 
2013). Thus, it can be speculated that targeting the TGF-β1 pathway could interfere with the 
accumulation of peritoneal CAFs.  
TGF-β signalling can also take place via Smad-independent pathways, which may or 
not converge with the Smad-dependent ones, involving the mitogen-activated protein kinases 
(MAPKs) extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) or p38, 
as well as nuclear factor-kappa B (NF-κB) and transforming growth factor beta-activated kinase 
1 (TAK-1) and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) (Derynck and Zhang 
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2003; Massagué and Gomis 2006; López-Cabrera 2014). However, Smad signalling has been 
reported to play a central role in the regulation of EMT (Valcourt et al. 2005). The Smad-
dependent activation or repression of gene transcription relies on the combination of Smads and 
co-activators or co-repressors in the nucleus, forming complexes that will selectively bind to the 
DNA (Figure 4) (Shi and Massagué 2003; de Caestecker 2004; Feng and Derynck 2005; 
Massagué and Gomis 2006; Derynck and Akhurst 2007).  
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Figure 4. Smad-dependent signalling pathways of TGF-β and BMP-7 in the MMT context. 
TGF-β is secreted in its latent form and, once activated, binds to the constitutively active TGF-β 
type II receptor (TGF-β R-II), which then phosphorylates the TGF-β type I receptor (TGF-β R-
I), activating it. BMP-7 has no latent form and binds its receptors in the same way. These 
receptors are transmembrane serine-threonine kinases. Once the receptors are activated, Smads 
2 and 3 (in the case of TGF-β1), and Smads 1, 5 and 8 (in the case of BMP-7) are 
phosphorylated and form a trimeric complex with Smad4 to translocate into the nucleus. In the 
nucleus, these complexes activate or repress target genes involved in either the mesenchymal 
conversion of MCs (MMT), in the case of Smads2/3, or in the blocking/reversion of the 
mesenchymal transition (rMMT), in the case of Smads1/5/8. Smad6 and Smad7 block the 
phosphorylation and/or nuclear translocation of Smads and induce receptor complex 
degradation by recruiting ubiquitin ligases. Modified from López-Cabrera, Advances in 
Medicine 2014. 
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5. Implication of mesothelial cells in adhesion, invasion and progression of peritoneal 
metastasis 
Independently of the MMT-promoting factors that could favour peritoneal metastasis, 
different hypotheses have tried to explain how malignant cells attach to the peritoneal 
membrane during the earliest stages. Initially, it was believed that MCs were simply victims of 
tumour aggression to the peritoneum (Heath et al. 2004; Na et al. 2010). Some experimental 
models proposed that intraperitoneal cancer spheroids gain access to the submesothelium by 
exerting force to clear MCs (Burleson et al. 2004; Iwanicki et al. 2011; Davidowitz et al. 2014). 
Subsequently, there was speculation that cancer cells do not adhere to the MCs but, rather, to 
the connective tissue under the MCs. The ECM is exposed in areas in the omentum (a fold of 
peritoneum containing fat tissue) called “milky spots” that have been identified as the preferred 
sites for peritoneal colonization (Hagiwara et al. 1993; Tsujimoto et al. 1995; Clark et al. 2013). 
However, “milky spots” are structures essentially comprised of an accumulation of immune 
cells and capillaries where the triggering of an inflammatory response can influence peritoneal 
metastasis, transforming the initial pattern of the “milky spot” attachment into a widespread 
pattern of dissemination (Sodek et al. 2012). In this context, De Vlieghere et al. have recently 
shown that microparticles coated with CAF-derived ECM proteins are able to selectively 
capture floating cancer cells, delaying tumour adhesion to the natural mesothelial niche (De 
Vlieghere et al. 2015). In the binding of cancer cells to the mesothelium, a wide range of 
adhesion molecules are reportedly involved, including CD44, CA125/MUC16, intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) (Casey and 
Skubitz 2000; Ziprin et al. 2003; Rump et al. 2004; Alkhamesi et al. 2005; Ksiazek et al. 2010; 
Yu et al. 2010; Wagner et al. 2011). However, a growing body of experimental evidence on 
adhesion concurs that, at initial stages of peritoneal metastasis, cancer cells adhere to the 
peritoneum in a β1-integrin-dependent manner (Takatsuki et al. 2004; Watanabe et al. 2012; 
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Chen et al. 2015), which could indicate the adhesion is associated to the ECM. In agreement 
with this notion, it has been reported that cleavage of MC-associated matrix proteins fibronectin 
and vitronectin by MMP-2 enhances integrin-mediated carcinoma–mesothelium attachment 
(Kenny et al. 2008; Kenny and Lengyel 2009).  
 
After attaching to the mesothelial monolayer, tumour cells reach the submesothelial 
compact zone. MCs increase their migration/invasion capacity during the MMT (Strippoli et al. 
2012). Accordingly, MCs have been considered as the advancing front of the tumour in the 
processes of peritoneal carcinomatosis (Satoyoshi et al. 2015a; 2015b). MCs behave in a similar 
fashion to resident fibroblasts, in terms of the induction of carcinoma cell invasion in vitro. It 
has been shown that normal omentum fibroblasts induce the adhesion and invasion of 
carcinoma cells in 3D culture models (Kenny et al. 2007; 2008). On the other hand, Cai et al. 
reported that activated fibroblasts (either CAFs isolated from omentum from patients with 
ovarian cancer metastasis or normal omentum fibroblasts stimulated with TGF-β1) have 
stronger effects on carcinoma cell attachment and invasion than normal fibroblasts (Cai et al. 
2011). Furthermore, the growth dynamics of cancer xenografts produced in response to 
intraperitoneal co-injection of omental MCs with either ovarian (Mikula-Pietrasik et al. 2014) or 
gastric (Tsukada et al. 2012) cancer cells was remarkably greater than for implantation of cancer 
cells alone. Therefore, in stark contrast to initial impressions, it is now accepted that MCs are 
not a passive barrier that prevents the progression of the tumour into the peritoneum, but are 
able to actively promote the process of adhesion to and invasion through the peritoneum. 
 
In order for tumour cells to migrate and/or invade through the colonized organs, ECM 
disruption is crucial (Schropfer et al. 2010). Matrix metalloproteinases (MMP) are known to be 
important molecular players in the physiological processes of cancer progression by facilitating 
angiogenesis and tumour invasion through matrix degradation (John and Tuszynski 2001; 
Kessenbrock et al. 2010; Al-Alem and Curry 2015). In this context, CAFs have been widely 
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implicated in the remodeling of the ECM components through MMPs to consequently favour 
cancer invasion (Taddei et al. 2013; Paulsson and Micke 2014). It is well known that, at an 
intermediate stage of EMT, cells acquire the capacity to degrade the basement membrane and to 
invade the fibrotic stroma by upregulating the expression of MMPs (Kalluri and Weinberg 
2009). In MCs, the expression of MMP-2 and MMP-9 increases in response to MMT-inducing 
stimuli such as TGF-β (Margetts et al. 2005) or TNF-α (Zhu et al. 2002). Interestingly, both of 
these MMPs can activate the latent form of TGF-β (Yu and Stamenkovic 2000). In addition, 
fibroblasts in omentum that have been activated by tumour cells have shown to promote ovarian 
invasiveness via MMP-2 overexpression (Cai et al. 2011). Similarly, exosomes of ovarian 
cancer ascites contain MMP-2, MMP-9 and urokinase-type plasminogen activator (uPa), all of 
them able to degrade the ECM, facilitating invasion and dissemination of tumour cells (Graves 
et al. 2004). Additionally, expression of VEGF by ovarian cancer cells is involved in 
transforming the ECM by stimulating MMP-9 expression at the tumour site (Belotti et al. 2008). 
With regard to the peritoneal environment, it could be speculated that, by increasing ECM 
deposition and MMP expression, mesothelial-derived CAFs regulate their own invasive 
capacity while helping to provide the appropriate ECM scaffold for cancer cells to survive in the 
metastatic niche (Birkedal-Hansen et al. 1993; Liotta and Kohn 2001; Lee et al. 2013; 2014). 
 
CAFs in the tumour compartment have been implicated in promoting the growth and/or 
proliferation of cancer cells, ensuring their survival at the colonized organ. Although, 
mesothelial-derived CAFs have not yet been implicated in directly augmenting tumour growth, 
some authors have suggested that MCs establish communication with the tumour by secreting 
proliferating stimuli or by direct cell-cell contact which, in turn, stimulate proliferation of 
cancer cells and drive peritoneal dissemination (Tsukada et al. 2012; Mikula-Pietrasik et al. 
2014). 
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At advanced stages of peritoneal metastasis, vascularization is necessary for tumour 
progression. Angiogenesis is also influenced by the organ microenvironment and is the result of 
an imbalance between positive and negative angiogenic factors released by tumour and host 
cells into the microenvironment of the neoplastic tissue (Kitadai 2010). In ovarian cancer 
progression in particular, the key role of VEGF has been well established and is correlated with 
decreased overall survival (Winiarski et al. 2014). Interestingly, vascular endothelial growth 
factor (VEGF) appears as one of the most induced factors in MCs transformed into 
myofibroblasts (Aroeira et al. 2005; Pérez-Lozano et al. 2013). The fact that the MCs that have 
undergone MMT express high amounts of VEGF suggests that peritoneal CAFs may play an 
important role in tumour vascularization (Sako et al. 2003).  
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The general objective of this doctoral thesis is to study the role of the mesothelial-to-
mesenchymal transition (MMT) in peritoneal metastasis. This objective can be divided into the 
following: 
 
 
1. Identify and characterise the mesothelial (MC)-derived carcinoma-associated 
fibroblasts (CAFs) in the metastatic peritoneum. 
 
2. Develop a mouse model to study peritoneal metastasis. 
 
3. Study the effect on the peritoneum of a pre-conditioning that will induce or block 
the MMT in the mouse model. 
 
4. Investigate the molecular mechanisms involved in the cancer cell-mesothelial cell 
interaction. 
 
5. Obtain a gene profile for MC-derived CAFs to identify new possible therapeutic 
targets. 
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1. Human samples 
1.1. Biopsies from patients with peritoneal metastasis 
Parietal peritoneum biopsies obtained from patients diagnosed with peritoneal 
carcinomatosis were considered in this study. Peritoneal metastases from eight serous ovarian 
carcinomas, four colonic adenocarcinomas, three pancreatic adenocarcinomas, one endometrial 
adenocarcinoma and pleural metastases from three pulmonary adenocarcinomas were 
considered in this study. Informed written consent to use surgical samples was obtained from 
the patients with the approval of the Ethics Committee of the Hospital Universitario de la 
Princesa (Madrid, Spain) and MD Anderson Cancer Center (Houston, USA). Tissue samples 
were fixed in neutral-buffered 3.7% formalin during 12-24 hours and embedded in paraffin to 
obtain serial sections 3-4 µm thick for histopathological analysis.  
1.2. Primary mesothelial cells 
Human peritoneal mesothelial cells (HPMCs) were obtained by trypsinization of 
omentum samples of patients undergoing unrelated abdominal surgery, as previously described 
(Yanez-Mo et al. 2003). Cells were cultured in Earle’s M199 medium supplemented with 20% 
fetal bovine serum (FCS), 50 U/ml penicillin, 50 mg/ml streptomycin and 2% Biogro-2 
(containing insulin, transferrin, ethanolamine and putrescine; Biological Industries, Beit 
Haemek, Israel). 
MCs were also obtained from the ascitic fluid of eight ovarian cancer patients with 
peritoneal dissemination. The ascitic fluid was centrifuged and subsequently cultivated in 
Earle’s 199 Medium. The purity of MC cultures was determined in both cases after 2-4 passages 
by the analysis of standard mesothelial markers (ICAM-1 and calretinin). The mesothelial cell 
type was confirmed by immunofluorescence staining using an antibody against calretinin 
(BioGenex, Fremont, CA, USA). Cell type was also confirmed by flow cytometry with 
antibodies against ICAM-1 (kindly provided by Dr. F. Sánchez-Madrid, Hospital Universitario 
de La Princesa, Madrid) using a BD FACSCalibur™ II flow cytometer (BD Biosciences, San 
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Jose, CA, USA). Cultures were negative for CD45, ruling out any contamination with 
macrophages. 
Informed written consent to use omentum samples and ascitic fluid was obtained from 
the patients with the approval of the Ethics Committee of the Hospital Universitario de la 
Princesa (Madrid, Spain) and MD Anderson Cancer Center (Houston, USA). These studies 
adjust to the Declaration of Helsinki and were approved by the Ethics Committee of Centro de 
Biología Molecular “Severo Ochoa” (Madrid, Spain). 
2. Cell culture and in vitro assays 
2.1. Cell lines 
The cell lines SKOV-3 and HT29, derived from human ovarian carcinoma and 
colorectal adenocarcinoma, respectively, were cultured in McCoy’s 5A medium supplemented 
with 10% fetal bovine serum (FBS) at 37 ºC, 5% CO2 atmosphere. HEK-293 cells were cultured 
in DMEM medium supplemented with 10% FBS at 37 ºC, 5% CO2 atmosphere. 
2.2. Induction of MMT in vitro 
Induction of MMT in vitro is performed by treatment of MCs with 0.5 ng/mL of 
transforming growth factor-β1 (TGF-β1) (R&D Systems, Minneapolis, MN) plus 2.5 ng/mL of 
interleukin-1β (IL-1β) (R&D Systems) (T+I) for 72 hours or 6 days, which has been proven to 
be a suitable MMT model (Yanez-Mo et al. 2003; Strippoli et al. 2008; Aroeira et al. 2009; 
Sandoval et al. 2010; Loureiro et al. 2011; Strippoli et al. 2012; Pérez-Lozano et al. 2013). 
To induce MMT with conditioned medium, sub-confluent omentum MCs, grown in 12-
well plates, were treated with 75% of carcinoma cells supernatants supplemented with 2% FBS 
during 72 hours or 6 days. Untreated MCs were maintained in fresh medium supplemented with 
2% FBS. At least 5 experiments were performed and each one was carried out in duplicate. 
To obtain conditioned medium, confluent SKOV-3 and HT29 cells cultures were 
maintained in serum-free medium for 24 hours. Supernatants were then collected, centrifuged 
and stored at -80 ºC until used.  Analysis of TGF-β1 in collected supernatants was achieved by 
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standard enzyme-linked immunoassay (ELISA) according to the manufacturer’s instructions 
(R&D Systems).   
2.3. Adhesion assays 
To analyse the adhesion molecules involved in cell-cell interaction, MCs treated or not 
with T+I were plated in 96-microwell plates until confluence. SKOV-3 cells were loaded with 
the fluorescent probe BCECF-AM (Sigma-Aldrich), following manufacturer instructions, and 
subsequently added (1x105 cells/well) to the MC monolayers in presence or absence of the 
indicated monoclonal antibodies (20 µg/mL) in RPMI 1640 medium. Cells were maintained at 4 
ºC for 10 min to allow antibody recognition and then allowed to adhere for 20 min at 37 ºC. 
Non adhered cells were washed with warm medium. Cells were measured by fluorescence of 
BCECF-AM with a fluorescence bottom reader (Tecan GENios). The percentage of adhesion 
was calculated considering the number of cells prior to wash as 100% of adhesion. The 
following monoclonal antibodies were applied in at least 3 experiments: Lia1/2 (blocking 
CD29); TS2/16 (activating CD29); 5E8D9 (blocking VLA-1); Lia 3/2 (blocking CD18) (Arroyo 
et al. 1992; Campanero et al. 1992). 
2.4. Invasion assays 
Invasion assays were performed in 12-mm diameter transwell units (3.0 µm pore size; 
Corning, MA, USA). First, the effect of carcinoma cells embedded in the matrix on MCs 
invasion capacity was analysed. Inserts were pre-coated with 300 µL of 1.5 mg/mL of rat-tail 
collagen I (BD Biosciences, San Jose, CA, USA) containing or not 2x105 CFSE-labelled 
SKOV-3 cells. After gelling overnight at 37 ºC, 2x105 MCs, resuspended in 200 µL of serum-
free M199 medium, were added into the upper chamber. Assay medium supplemented with 5% 
FBS was added to the lower chamber. MCs were allowed to invade for 5 days at 37 ºC, 5% CO2 
atmosphere. To analyse the effect of MCs on carcinoma cell invasion, the inserts were collagen 
I pre-coated containing or not 2x105 CFSE-labelled MCs with either epithelial-like or 
mesenchymal-like phenotype. After gelling, 2x105 SKOV-3 cells, resuspended in 200 µL of 
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serum-free McCoy’s 5A medium were added into the upper chamber, and medium 
supplemented with 5% FBS was added to the lower chamber. Tumour cells were allowed to 
invade for 5 days at 37 ºC, 5% CO2 atmosphere. In all the cases, the transwells were then fixed 
in 10% formaldehyde and stained with propidium iodide (Sigma-Aldrich).  
Images were captured by using a confocal laser-scanning microscope (LSM 710; Carl 
Zeiss MicroImaging), equipped with acquisition software (Zeiss Zen 2008), and using 10x 
objective. 3D double-color imaging was performed using the program ImageJ 1.46f (National 
Institutes of Health). 
Parallel experiments were subjected following the same procedure to obtain 3-4 µm 
transversal sections of paraffin embedded gels. Images of H&E stained sections were acquired 
by optical microscope. Each experiment was carried out in duplicate and at least 3 experiments 
were performed. 
2.5. Treatment of mesothelial and cancer cells with TGF-β1 
HPMCs and SKOV-3 cells were plated at confluence on 22 mm2 coverslips placed in 
24-well tissue culture plates. Where indicated, cells where stimulated with TGF-β1 (4 ng/ml) 
for 1 and 6 hours. Coverslips were fixed in 4% paraformaldehyde and stained by 
immunofluorescence for phosphorylated Smad3 (pSmad3) (Cell Signaling). 
3. Adenoviral production 
HEK 293 A cells were infected with a control adenovirus or with an adenovirus 
encoding active TGF-β1, kindly provided by Fernando Rodríguez-Pascual (Otsuka et al. 2006). 
4 days post-infection, adenoviral particles were recollected and purified with Adeno-X™ Maxi 
Purification Kit (Clonetch Laboratories, Mountain View, CA, USA) and later titrated with 
Adeno-X™ Rapid Titer Kit (Clontech). 
4. Bacterial transformation, lentiviral vector production and titration 
Plasmids containing the shRNA sequence targeting Smad3, and control plasmids 
(SHC003) were purchased from Sigma-Aldrich (St. Louis, MI, USA) in the pLKO.1-puro-
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CMV-TurboGFP™ backbone. The MISSION® shRNA used was 
TRCN0000089026:5’CCGGCTGTCCAATGTCAACCGGAATCTCGAGATTCCGGTTGAC
ATTGGACAGTTTTTG-3’. 100 µl of competent bacteria were mixed with 10 ng of each 
plasmid and incubated on ice for 30 min. A 42 °C heat-shock of 30 s was performed, followed 
by immediate placement on ice for 5 min. 200 µl of SOC medium were added to the bacterial 
suspensions before incubating at 37 °C for 1 h. Half of each the aliquot was plated out on 1.5% 
(w/v) LB agar plates with 100 µg/ml ampicillin at 37 °C overnight. The following day, single 
colonies were incubated in 200 ml of LB at 37 °C for 24 h. The LB medium was recollected and 
centrifuged at 4 ºC and 6,000 g for 20 min. The pellets obtained were used to purify the plasmid 
DNA with the QIAGEN Plasmid Maxi Kit (QIAGEN, Hilden, Germany) following 
manufacturer’s instructions. Pseudoviral particles were prepared using the pPACK‐F1 
Lentivector packaging system (SBI System Biosciences, Mountain View, CA, USA) and HEK 
293T producer cell line were used as described (Ding and Kilpatrick 2013). The titration of 
pseudoviral particles generated with the lentiviral vectors was determined by calculating the 
percentage of positive GFP expression cells by flow cytometry in a BD FACSCalibur™ II flow 
cytometer (BD Biosciences, San Jose, CA, USA) 72 h after infection. The lentivirus titers were 
calculated as described (Ding and Kilpatrick 2013) and expressed in infection forming units 
(ifu)/ml. 
5. Mice 
Swiss nu/nu 2-month-old mice were used in all studies (Charles River Laboratories, 
Barcelona, Spain). Food and water were provided ad libitum to the animals. The experimental 
protocols followed were in accordance with the National Institutes of Health Guide for Care and 
Use of Laboratory Animals and were approved by the Animal Ethics Committee of the “Unidad 
de Experimentación Animal” del Centro de Biología Molecular “Severo Ochoa” (Madrid, 
Spain). 
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5.1. Mouse model of carcinoma peritoneal dissemination  
A total of 5x106 SKOV-3 cells resuspended in 1000 µL of phosphate buffered saline 
(PBS) were inoculated into the peritoneal cavity of mice (n=10). Mice were sacrificed at 
different time points (four to eight weeks) and parietal peritoneum samples were collected for 
immunohistochemical analysis. 
5.2. Subcutaneous xenografts 
A preliminary assay with mice (n=2) co-inoculated in the left flank with 1x106 SKOV3-
luc-D3 Bioware® cells alone, and in the right flank with 1x106 SKOV3-luc-D3 Bioware® cells 
plus and 0.5x106 ascitic fluid-derived MCs (AFMCs). Mice were co-inoculated in the left flank 
with a combination of 1x106 SKOV3-luc-D3 Bioware® cells and 0.5x106 HPMCs resuspended 
in 100 µL of PBS. One the right flank, mice were co-inoculated with 1x106 SKOV3-luc-D3 
Bioware® and either 0.5x106 HPMCs T+I in one group (n=8), or 0.5x106 AFMCs (n=6), all 
resuspended in 100 µL of PBS. Upon injection of D-luciferin (Perkin-Elmer, Hopkinton, MA, 
USA), luciferase signal was detected and tumour growth was monitored weekly for 5 weeks 
with IVIS Lumina II (Perkin-Elmer). 
5.3. Peritoneum pre-conditioning 
5.3.1. Adenoviral delivery of TGF-β1 
In order to induce a mesothelial-to-mesenchymal transition and pre-condition the 
peritoneum, the TGF-β1 gene was transduced into the peritoneal cavity with adenoviral vectors. 
Mice were infected with control adenovirus 1x107 (n=6) or adenovirus encoding active TGF-β1 
(n=6). 7 days post-infection, mice were inoculated i.p. with 5x106 SKOV3-luc-D3 Bioware® 
resuspended in 1000 µL of PBS. Upon injection of D-luciferin (Perkin-Elmer), luciferase signal 
was detected and mice were monitored twice weekly with IVIS Lumina II (Perkin-Elmer, 
Hopkinton, MA, USA). Mice were sacrificed 41 days post-inoculation and parietal peritoneum 
samples were collected for immunohistochemical analysis. !  
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5.3.2. Conditioned medium from cancer cells 
In order to induce a mesothelial-to-mesenchymal transition, conditioned medium from 
SKOV-3 cells (maintained in McCoy’s 5A medium supplemented with 1% serum for 48 hours) 
was administered intraperitoneally (i.p.) to mice 2 days prior to the inoculation in the peritoneal 
cavity of 5x106 SKOV3-luc-D3 Bioware® cells (Perkin-Elmer, Hopkinton, MA, USA) 
resuspended in 1000 µL of PBS. The conditioned medium had been previously centrifuged and 
stored at -80 ºC until use. MMT was blocked with a TGF-β receptor I inhibitor, GW788388 (3 
mg/kg/day, Tocris Bioscience, UK), and the vehicle DMSO was used as a control. GW788388 
was administered into the peritoneal cavity 4 and 2 days prior to mice being inoculated with 
5x106 SKOV3-luc-D3 Bioware® cells. 4 groups of 6 mice each were used. Mice and tumour 
growth were monitored by in vivo bioluminiscence imaging twice weekly with IVIS Lumina II 
(Perkin-Elmer, Hopkinton, MA, USA). Mice were sacrificed 41 days post-inoculation and 
parietal peritoneum samples were collected for immunohistochemical analysis. 
5.3.3. Smad3 knockdown with lentiviral delivery 
18 mice were randomly grouped to be infected with 1x109 ifu of either control or 
Smad3 shRNA-producing lentiviral particles (obtained as described later). 4 days post-infection, 
mice were inoculated i.p. with 5x106 SKOV3-luc-D3 Bioware® resuspended in 1000 µL of 
PBS. Upon injection of D-luciferin (Perkin-Elmer), luciferase signal was detected and mice 
monitored twice weekly with IVIS Lumina II (Perkin-Elmer, Hopkinton, MA, USA). Mice were 
sacrificed 41 days post-inoculation and parietal peritoneum samples were collected for 
immunohistochemical analysis. 
6. Immunohistochemical analysis 
6.1. Human samples 
Deparaffinized tissues were heated to expose the hidden antigens using Real Target 
Retrieval Solution containing citrate buffer, pH 6.0 (Dako, Glostrup, Denmark). Endogenous 
peroxidase was blocked with Real Peroxidase-Blocking Solution (Dako). Samples were stained 
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using primary antibodies to detect pan-cytokeratin (Dako); α-SMA (Dako); Calretinin 
(Novocastra Laboratories, Newcastle Upon Tyne, UK); Mesothelin (Roche Diagnostics); 
Cytokeratin-20 (Dako); Cytokeratin-7 (Dako); Cytokeratin AE1/AE3 (Roche Diagnostics), 
CD34 (Dako), pSmad3 (Cell Signaling), VEGF (Abcam, Cambridge, UK) and WT1 (Roche 
Diagnostics). Antibodies were visualized by means of a dextran–polymer conjugate technique 
(EnVision+, Dako) using 3,3′-diaminobenzidine (DAB) (Dako) as chromogen. Tissue sections 
were counterstained with haematoxylin. 
6.2. Mouse samples 
Similarly, mouse deparaffinized peritoneal samples were incubated with the following 
primary antibodies: α-SMA (Sigma-Aldrich, St Louis, MO, USA); pan-cytokeratin (Sigma-
Aldrich); CD31 (Abcam, Cambridge, UK); pSmad3 (Cell Signaling), and WT1 (Santa Cruz 
Biotechnology, INC). Non-specific binding of secondary antibodies was blocked by pre-treating 
slides with goat serum. A Biotinylated goat anti-rabbit IgG (H+L) was applied to detect rabbit 
primary antibodies and complexes were visualized using the R.T.U Vectastain Elite ABC Kit 
(Vector Laboratories, Burlingame, CA, USA). Mouse primary antibodies were visualized 
applying the Vector M.O.M. Immunodetection Kit (Vector Laboratories) according to the 
manufacturer’s instructions. Tissue sections were revealed using DAB (Dako) as chromogen 
and finally counterstained with haematoxylin. 
7. Immunofluorescence analysis 
7.1. Peritoneal tissues from mice 
Deparaffinized tissues were stained for immunofluorescence with antibodies to 
visualize WT1 (Santa Cruz Biotechnology) and α-SMA (Sigma-Aldrich). Sections were heated 
to expose the hidden antigens using Real Target Retrieval Solution containing citrate buffer, pH 
6.0 (Dako). Non-specific binding of secondary antibodies was blocked by pretreating slides 
with donkey serum (Abcam). Secondary antibodies Alexa Fluor 647 and Alexa Fluor 555 were 
incubated (Molecular Probes) at room temperature. Finally, the slides were mounted with a 4',6-
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diamidino-2-phenylindole (DAPI) nuclear stain (Pierce; Thermo Fisher Scientific). The 
preparations were analysed with a Leica TCS-SP5 (Leica Microsystems) confocal microscope. 
7.2. Mesothelial and SKOV-3 cells 
Cells were fixed for 10 minutes in 4% paraformaldehyde and permeabilized 10 minutes 
in 0.1% NP-40. In all cases, 5% goat serum was applied for 20 minutes to block non-specific 
unions. Cells were stained for calretinin (labeled with Alexa Fluor 488), α-SMA (labeled for 
Alexa Fluor 555) and pSmad3 (labeled with Alexa Fluor 488) and mounted with fluorescent 
mounting medium (Dako). Confocal images were acquired with a LSM710 Zeiss Confocal 
Microscope, equipped with acquisition software (Zeiss Zen 2008) and using 40X or 60X 
objectives.  
8. Flow cytometry 
Confluent cultures of ascitic fluid-derived MCs were trypsinized, washed and 
resuspended in PBS supplemented with 0.5% BSA and 2 mM EDTA. A total of 1x105 cells 
were incubated with 100 µl of polyclonal antibody against ICAM-1 washed with PBS and then 
incubated with 100 µl of a 1:50 dilution of an Alexa Fluor 488 anti–mouse Ig. Finally, 
fluorescence was measured using a BD FACSCalibur™ II flow cytometer (BD Biosciences, 
San Jose, CA, USA). 
9. Western blot 
MC and SKOV-3 cultures were lysed in RIPA buffer (1% sodium deoxycholate, 0.1% 
sodium dodecyl sulphate) plus a phosphatase and protease inhibitor cocktail (Pierce) and total 
protein was quantified by protein assays kit (Pierce). Equal amounts of denatured proteins (20 
µg) from each sample were resolved by 8–10% sodium dodecyl sulphate–polyacrylamide gel 
electrophoresis under reducing conditions. Proteins were transferred on nitrocellulose 
membranes, which were then blocked with 5% non-fat milk in TBS–Tween buffer for 1 h and 
incubated with specific antibodies against WT1 (Santa Cruz Biotechnology), α-SMA (Sigma-
Aldrich), pan-cytokeratin (Sigma-Aldrich), calretinin (Biogenex, CA, USA) and β-actin 
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(Sigma-Aldrich) in 0.5% milk in TBS-Tween overnight at 4 °C. These antibodies were detected 
with a peroxidase-conjugated goat anti-mouse and donkey anti-rabbit antibodies (Pierce), and 
then were visualized with enhanced chemiluminescence (ECL) detection kit (Pierce). Blot 
images were acquired using a GS-710 Imaging Densitometer (Bio-Rad, Hercules, CA, USA). 
10. Quantitative real-time PCR (qRT-PCR) 
The analysis of MMT-related molecules was achieved by real time qRT-PCR. Briefly, 
MCs were lysed in TRI Reagent (Ambion, Inc., Austin, TX) and total RNA was extracted 
according to the manufacturer’s recommendation. Complementary DNA was obtained from 2 
µg of RNA by reverse transcription (Applied Biosystems, Cheshire, UK). Quantitative PCR was 
carried out in a LightCycler 2.0 using a SYBR Green kit (Roche Diagnostics, Mannheim, 
Germany) and specific primers for Snail, E-cadherin, fibronectin, collagen I, vascular 
endothelial growth factor (VEGF), TGF-β1, and histone H3 (Table 1). Samples were 
normalized with respect to the value obtained for H3. 
Table 1. Specific primers for real-time PCR 
Gene Forward primer Reverse primer 
Tm 
(ºC) 
Snail 5!-GCAAATACTGCAACAAGG-3! 5!-GCACTGGTACTTCTTGACA-3! 55 
E-cadherin 5!-TGAAGGTGACAGAGCCTCTG-3! 5!-TGGGTGAATTCGGGCTTGTT-3! 62 
Fibronectin 5!-CCTGAAGCTGAAGAGACTTGC-3! 5!-CGTTTCTCCGACCACATAGGA-3! 66 
Collagen I 5!-GCTATGATGAGAAATCAACCG-3! 5!-GCTTCCCCATCATCTCCATTC-3! 64 
VEGF-A 5!-GCAGAAGGAGGAGGGCAGAAT-3! 5!-TATGTGCTGGCCTTGGTGAGG-3! 60 
TGF-β1 5!-TGAACCGGCCTTTCCTGCTTCTCATG-3! 5!-CGGAAGTCAATGTACAGCTGCCGC-3! 70 
H3 histone 5!-AAAGCCGCTCGCAAGAGTGCG-3! 5!-ACTTGCCTCCTGCAAAGCAC-3! 62 
 
11. Scanning electron microscopy 
MCs were plated at confluence on 22 mm2 coverslips placed in 24-well tissue culture 
plates. Where indicated, cells where stimulated with T+I for 72 hours, and then washed twice. 
SKOV-3 cells labeled with Carboxyfluorescein diacetate Succinimidyl Ester (CFSE; Molecular 
Probes, Invitrogen) were added at a density of 1 x 105 cells per well. After 30 minutes, the wells 
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were gently washed to eliminate non-attached cells. Coverslips were then fixed in 4% 
paraformaldehyde and nuclei were stained with DAPI. Adherent SKOV-3 cells were evaluated 
in ten fields per sample. Representative images were captured with a digital camera coupled to a 
vertical fluorescence microscope (Axioskop2 plus, Carl Zeiss, INC). At least 5 experiments 
were performed in duplicate. 
For scanning electron microscopy analysis, a parallel experimental procedure was 
carried out in which coverslips were fixed in 3% glutaraldehyde. Post-fixation was performed in 
1% OsO4 and after dehydration through graded series of ethanol, samples were dried in a 
critical-point drying system using liquid carbon dioxide. Finally, coverslips were mounted on 
aluminum stubs, sputter coated with gold, and examined using a scanning electron microscope 
(JEOL Scanning T-300). Images were interpreted using the image-processing program ImageJ 
1.46f (National Institutes of Health, Bethesda, Maryland, USA). 
12. Statistical analysis 
Results are presented as 25th and 75th percentiles, median, minimum and maximum 
values in box plots graphics; and as mean ± SEM in bar graphics. Statistical analysis was 
performed using GraphPad Prism version 5.0 (La Jolla, CA, USA). Data groups of Figures 8, 
16, 17, 18, 19, 20, 21, 22 and 27 were compared with the non-parametric Mann–Whitney rank 
sum U-test. Multiple t-test analysis was performed in Figures 23, 25, 26 and 31. p < 0.05 was 
considered statistically significant in all cases. 
13. RNA-sequencing and functional annotation 
13.1. RNA extraction 
Total RNA was extracted from HPMCs and AFMCs by lysing in TRI Reagent 
(Ambion, Inc., Austin, TX) following manufacturer’s recommendation. Before performing the 
RNA sequencing, RNA integrity was checked using the Agilent Bioanalyzer 2100® (Agilent 
Technologies, Santa Clara, CA, USA). 
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13.2. RNA sequencing 
Samples were depleted of rRNA, then the RNA was sheared into smaller fragments 
with Covaris S220 (Covaris, Woburn, MA, USA). The cDNA library was prepared using the 
Beckman SPRIworks system (Beckman Coulter Inc., Fullerton, CA, USA). Library fragments 
hybridize to complementary oligonucleotides, and clusters of clones are generated in the 
Illumina cBOT instrument (Illumina, Inc., San Diego, CA, USA). The XX libraries were 
sequenced onto an Illumina HiSeq 2000 (Illumina, Inc., San Diego, CA, USA) and subjected to 
100 cycles of paired-end (200 bp insert size) sequencing, generating 412 million reads. 
13.3. Data analysis 
Raw sequences obtained from the Illumina platform in FASTQ format were analyzed 
using publicly available tools. Quality reads were analyzed using FastQC. Due to the high 
quality of reads there was no need to trim of filter them. The sequences were mapped to the 
GRCh38.p2 human reference genome sequence using a series of programs, including Bowtie2 
for short-read mapping, and TopHat for defining exon–intron junctions. The expression level of 
each transcript was expressed as the fragments per transcript kilobase per million fragments 
mapped (FPKM) value, which was calculated based on the number of mapped reads using 
Cufflinks. Cuffdiff was used to detect differentially expressed genes using three replicates. 
Heatmaps were generated using heatmap.2 in the R package gplots (ver. 2.11.0) with the Z-
scores of RPKM values. 
13.4. Analysis of differential expression genes by IPA software 
Genes that were differentially regulated were uploaded to the Igenuity Pathway 
Analysis (IPA) tool (Ingenuity® Systems, www.ingenuity.com) to perform analysis of 
canonical pathways and upstream regulators. Fisher's exact test was used to measure the 
significance of the association between the list of genes and a canonical pathway. Pathways 
with a p-value < 0.05 (Benjamini-Hochberg method) were considered to be statistically 
significant. When analysing the resulting pathways in order to study their relevance in the 
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context of ovarian cancer patients, canonical pathways that are specific to other cells types or 
unrelated pathologies have been excluded, e.g. “airway inflammation in asthma”, “axonal 
guidance signalling”. The upstream regulator analysis function was used to identify potential 
transcriptional regulators; and only the regulators that are also differentially expressed in our 
data set have been considered. Upstream regulator analysis takes into account two measures: the 
statistical significance of genes in the dataset to overlap with the list of downstream targets of a 
given regulator (p-value of overlap; p < 0.05 was considered significant), and the prediction of 
activation or inhibition of a putative regulator based on published findings included in the 
Ingenuity Knowledge Base (activation z-score; a z-score of ≥|2| was considered significant). 
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1. Human biopsies analysis shows that CAFs originate from MCs and collaborate in 
tumour angiogenesis. 
Histological observation of peritoneal biopsies from human ovarian carcinoma implants 
showed the localization of metastatic foci in the submesothelial area surrounded by spindle-like 
cells. Immunostaining of serial sections showed overlapped expression of α-smooth muscle 
actin (α-SMA) and mesothelial markers, such as cytokeratins and calretinin, in the stromal 
tissue surrounding the tumour implants. As expected, cytokeratin staining also revealed the 
epithelial nature of metastasizing cells (Figure 5A). Additional mesothelial markers, such as 
Wilm’s tumour protein-1 (WT1) and mesothelin, were also expressed in fibroblast-like cells 
proximal to peritoneal micrometastases derived from an endometrial adenocarcinoma (Figure 
5B). The co-expression of mesothelial and mesenchymal markers suggested that in peritoneal 
metastases CAFs may derive from MCs via MMT. 
Using the differential expression of cytokeratins, the  mesothelial origin of CAFs was 
confirmed; e.g. colon carcinoma cells express cytokeratin-20 but not cytokeratin-7 and, 
conversely, MCs express cytokeratin-7 but not cytokeratin-20. The analysis of peritoneal 
metastases of colon carcinoma in humans demonstrated that the expression of cytokeratin-20 
was confined to tumour implants, whereas the expression of cytokeratin-7 was observed in the 
preserved mesothelium of tumour-free regions and in fibroblast-like cells located in the close 
proximity of tumour micrometastases (Figure 5C). To further verify that CAFs may originate 
from MCs, metastatic implants of lung cancers in the pleura (another anatomical cavity lined by 
mesothelium) were analysed. Here, CAFs expressing calretinin close to cancer implants can be 
observed (Figure 6). In addition, there was no expression of mesothelial makers in CAFs of 
tumours located outside the coelomic cavities (Figure 7). 
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Figure 5. Analysis of human peritoneal carcinoma implants reveals the mesothelial origin 
for CAFs. 
(A) (a) H&E staining shows an ovarian cancer micrometastasis in the submesothelial area, 
surrounded by spindle-like cells; (b–d) IHC analysis of serial sections reveals overlapped 
expression of α-SMA and the mesothelial markers calretinin and cytokeratin in fibroblastic cells 
surrounding the tumour implant; (d) cytokeratins also stain the metastasizing cells, revealing 
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their epithelial nature. Scale bars(=(25(µm. (B) Serial sections of a peritoneal implant of an 
endometrial cancer biopsy reveal the presence of (a) fibroblastic cells expressing nuclear WT1 
and (b) mesothelin detected within the endometrial tumour mass. Scale bars(=(100(µm. (C) 
Biopsy of peritoneal metastasis from a patient diagnosed with colon carcinoma: (a) multiple 
tumour nodules express cytokeratin-20 while stromal cells close to metastatic implants are 
negative for this marker; (b) in contrast, fibroblast-like cells surrounding tumour implants 
express the mesothelial marker cytokeratin-7; inset shows a higher magnification of the 
delimited area. Scale bars(=(100(µm. T, tumour. 
!
Figure 6. Analysis of human lung cancer-derived metastasis in the pleura. 
Calretinin-positive fibroblasts coexist with large-cell lung carcinoma implants in pleura. These 
results support the mesothelial origin of CAFs. T, tumour. Scale bars(=(100(µm. 
!
Figure 7. MC markers are not expressed in CAFs of tumours located outside the coelomic 
cavities. 
(A, B) Serial sections of a cutaneous basal cell carcinoma show CAFs negative for mesothelial 
markers (cytokeratin AE1/AE3 and calretinin) accompanying the tumour. (C) An infiltrating 
breast carcinoma positive for cytokeratin AE1/AE3 shows proximal CAFs negative for this 
mesothelial marker. Scale bars(=(25(µm. T, tumour. 
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It has been shown that during the MMT, MCs acquired the ability to produce large 
amounts of VEGF (Aroeira et al. 2005; Pérez-Lozano et al. 2013). Thus, it can be hypothesized 
that CAFs derived from MCs may play a role in tumour vascularization. Quantification of the 
number of vessels in biopsies from peritoneal implants derived from different human cancers 
revealed a significant increase (p=0.002) in CD34-positive vessels in the areas of tumour 
micrometastasis compared with tumour-free zones from the same biopsies (Figure 8A–C). To 
confirm that MC-derived CAFs participate in tumour angiogenesis, tumours that express low 
levels of VEGF were used. As shown in Figure Figure 9A, an endometrial adenocarcinoma 
expressed low amounts of VEGF. In contrast, MC-derived CAFs (cytokeratin-positive) 
appeared to be high producers of VEGF (Figure 9B). 
!
Figure 8. Vessel number increases in areas adjacent to micrometastases. 
(A) Representative specimen of ovary cancer metastasis in peritoneum. The “Non-Tumour” 
image shows a submesothelial area from the biopsy without evidence of tumour implants and 
with a low number of vessels, which were mostly confined to the deeper compact zone. The 
“Tumour” image depicts a submesothelial area with micrometastases and elevated number of 
CD34-positive vessels. Scale bars(=(100(µm. (B) Separate analysis of three ovarian, two 
pancreatic, one colorectal and one endometrial-derived metastases consistently shows the 
differences. (C) Quantification of CD34-positive vessels observed in tumour implant areas 
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compared to distant zones without evidence of peritoneal metastases. Box plot graphic depicts 
25th and 75th percentiles, median, minimum and maximum values; differences were 
statistically significant (p = 0.002). Scale bars(=(25(µm. T, tumour. 
!
Figure 9. MC-derived CAFs accumulate close to micrometastases and express large 
amounts of VEGF. 
(A) Representative case of endometrial adenocarcinoma metastasis in peritoneum: (a) tumour 
implant shows low expression levels of VEGF, which is mostly limited to endothelial cells in 
angiogenesis areas; (b) spindle-shaped CAFs surrounding the tumour mass express high levels 
of VEGF. Scale bars(=(25(µm. (B) (a, b) Serial sections of the same case confirm that MC-
derived CAFs (cytokeratin-positive) proximal to the tumour produce large amounts of VEGF. 
Scale bars(=(25(µm. T, tumour. 
2. CAFs originate from MCs in a mouse model of peritoneal dissemination 
Parietal peritoneal tissues stained with H&E showed a fibro-proliferative response at the 
sites of small tumour implants, with submesothelial accumulation of spindle-like cells and 
fibrosis, which were absent in tumour-free zones of the same samples (Figure 10A, B). 
Immunohistochemistry analysis showed intense cytokeratin staining of metastasizing cells and a 
weak cytokeratin staining in MCs located nearby, indicating that these MCs were undergoing a 
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MMT, which implied the downregulation of cytokeratin expression. Surrounding the 
micrometastatic nodules there was a prominent accumulation of α-SMA-positive fibroblasts. In 
the peritoneal region without metastatic implants there was no expression of α-SMA other than 
that in the smooth muscle cells of the vessel walls, and the expression of cytokeratin was 
limited to the preserved mesothelium (Figure 10C–F). WT1 was used as an additional 
mesothelial marker in order to confirm the origin of CAFs. Immunohistochemistry analysis 
showed nuclear staining of WT1 in the preserved mesothelium of tumour-free regions and in 
submesothelial CAFs surrounding tumour implants (Figure 10G, H). Immunofluorescence 
techniques confirmed the presence of fibroblast-like cells that were double positive for WT1 
and α-SMA (Figure 11). Western blot analysis demonstrated that SKOV-3 cells were negative 
for WT1 and α-SMA, and confirmed the down-regulation of cytokeratin and induction of α-
SMA during the MMT (Figure 12). 
Blood vessels of parietal tissues were stained with anti-CD31 antibody. There was a 
dramatic increase in the number of vessels in areas adjacent to micrometastases when compared 
with tumour-free regions (Figure 13A, B). The new vessels were mainly located in the upper 
sub-mesothelial zone, where MC-derived CAFs expressing high levels of VEGF (Figure 13C, 
D) tended to accumulate, suggesting that MCs could, indeed, play an important role in tumour 
vascularization. 
Analysis of peritoneal specimens with larger implants showed that, at advanced stages 
of peritoneal dissemination, the expression of cytokeratin was restricted to carcinoma cells. 
Nevertheless, WT1- and α-SMA-positive cells could be observed, not only in the proximity of 
carcinoma implants, but also integrated within the tumour stroma (Figure 14). Peritoneal 
metastases were also observed in the omental tissue, where cytokeratin- and α-SMA-positive 
spindle cells were found in the interstitial stroma, surrounding tumour implants (Figure 15). 
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Figure 10. CAFs originate from MCs in a mouse model of peritoneal dissemination. 
Immunohistochemistry of parietal peritoneum samples, 4 weeks after i.p. injection of SKOV-3 
cells. (A, B) H&E staining shows areas distant from tumour implants (Non-Tumour) with a 
conserved histological structure, no evidence of fibrosis and with a preserved MC monolayer. 
At the places of tumour implants there is a fibro-proliferative response, with the accumulation 
of spindle-like cells. (C, D) Cytokeratin expression in the preserved mesothelium of “Non-
Tumour” regions. In the proximity of tumour implants, there is an intense cytokeratin staining 
in metastasizing tumour cells, but a weak cytokeratin staining in MCs and in some fibroblast-
like cells. (E, F) In the “Non-Tumour” areas there is no expression of α-SMA other than that in 
the smooth muscle cells of the vessel walls. Surrounding the tumour implants there is 
accumulation of α-SMA-positive fibroblasts. (G, H) Nuclear staining of WT1 (an additional 
MC marker) in the preserved mesothelium of tumour-free regions and in submesothelial CAFs 
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surrounding tumour implants. Arrows indicate MC-derived CAFs in the proximity of 
submesothelial tumour implants. Insets show higher magnifications of the delimited areas. Scale 
bars(=(25(µm. T, tumour; Pan-CK, pan-cytokeratin. 
 
Figure 11. Mesothelial-derived CAFs co-express WT1 and α-SMA in the mouse model of 
peritoneal dissemination. 
(A) Peritoneal tissue from a non-tumour-bearing mouse shows nuclear WT1 confined to the 
preserved MC monolayer, where there is no expression of α-SMA. (B) Distant areas from 
tumour micro-implants show MCs forming a monolayer and expressing nuclear WT1 (green). 
MCs lining the peritoneum are exposed to factors produced by the tumour and, as a 
consequence, MCs with an apparently preserved structure begin to express low levels of α-SMA 
(red). (C) In areas close to the micrometastasis, MCs co-expressing WT1 (green) and α-SMA 
(red) change their original localization on the peritoneal surface and start to invade the 
submesothelial compact zone. (D) CAFs co-expressing WT1 and α-SMA are embedded in the 
parenchyma of a micrometastasis cohabiting with tumour cells negative for both markers. 
Arrows indicate MC-derived CAFs co-expressing WT1 and α-SMA. Scale bars(=(10(µm. 
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Figure 12. Expression pattern of mesothelial markers in primary HPMCs, either treated 
or not with TGF-β1 plus IL-1β, and in SKOV-3 cells. 
Western blot analysis shows that SKOV-3 cells are negative for WT1, α-SMA and calretinin. 
The expression of pan-cytokeratin in SKOV-3 cells reveals its epithelial origin. On the contrary, 
HPMCs express WT1, pan-cytokeratin and calretinin. The levels of these markers are 
dramatically down-regulated in HPMCs treated with TGF-β1 + IL-1β (T+I). The molecule α-
SMA is increased in HPMCs transdifferentiated in vitro. Expression of β-actin is employed as a 
loading control. 
!
Figure 13. Increased angiogenesis is found in sites where MC-derived CAFs expressing 
high amounts of VEGF accumulate. 
(A, B) CD31 staining reveals that non-tumour zones do not possess a high number of vessels. 
At the sites of tumour implants, there is a dramatic increase of vessel density, particularly 
located in the upper compact zone where MC-derived CAFs tend to accumulate. (C, D) VEGF 
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is expressed in a preserved mesothelium distant from tumour implants. At tumour zones, MCs 
and MC-derived CAFs, as well as cancer cells proximal to vascularized areas, express high 
levels of VEGF. Arrows indicate angiogenesis zones. Scale bars(=(25(µm. T, tumour. 
!
Figure 14. Large tumour implants coexist with fibrotic areas where CAFs express 
mesothelial markers. 
H&E analysis of advanced peritoneal disseminations (8(weeks after i.p. SKOV-3 cell injection) 
shows larger metastatic masses coexisting with widespread areas of fibrosis. IHC studies reveal 
the existence of CAFs expressing mesothelial markers, not only in the proximity of carcinoma 
implants but also integrated within the tumour stroma. The expression of cytokeratin is 
restricted exclusively to carcinoma cells. However, extended WT1 and α-SMA staining can be 
observed cohabiting with the large peritoneal tumours. The inset shows a higher magnification 
of the WT1 nuclear staining. Scale bars(=(100(µm. T, tumour. 
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Figure 15. Analysis of omental metastasis in the mouse model of peritoneal dissemination. 
(A) Visceral macroscopic metastases are observed in mice i.p. inoculated with SKOV-3 cells. 
(B) Immunohistochemical analyses of omental tissues reveal that MCs positive for cytokeratin 
are lining omentum in tumour-free areas. (C) Fibroblastic cells (CAFs) express pan-cytokeratin 
in the stroma interstices between cancer cells. (D) α-SMA is negative in MCs lining tumour-free 
omental tissue. (E) A higher magnification of the tumour mass shows spindle-like cells positive 
for α-SMA embedded in the tumour parenchyma. Scale bars(=(100(µm (B, D) and 25(µm (C, E). 
Arrows indicate MCs expressing cytokeratin or α-SMA; T, tumour. 
3. Conditioned medium from carcinoma cells induces MMT in vitro 
Incubation of HPMCs with SKOV-3-cell-conditioned medium induced the acquisition 
of a spindle-like morphology that was evident at 72 h and more pronounced at 6 days, with a 
similar appearance to that of HPMCs treated with TGF-β1 plus IL-1β (T+I) (Figure 16A). To 
verify the mesenchymal conversion of HPMCs, the expression patterns of MMT markers were 
analysed by quantitative RT–PCR in cells treated with conditioned medium for 72 h. Under 
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these conditions, the expression of E-cadherin was repressed and, conversely, the expression of 
Snail was induced when compared with control medium-treated cells (Figure 16B, C). The 
expression of other MMT markers (fibronectin, collagen I, VEGF and TGF-β1) was upregulated 
in HPMCs treated with conditioned medium compared to control cells (Figure 16D-G). The 
molecular reprogramming was more profound after 6 days of treatment with SKOV-3-
conditioned medium (data not shown). 
Similar experiments were performed using the colorectal adenocarcinoma cell line 
HT29. Treatment of HPMCs with supernatant from HT29 cultures induced the acquisition of a 
spindle-like morphology, but this was evident only at 6 days (Figure 17). Repression of E-
cadherin and the up- regulation of fibronectin and collagen-I also reached statistical significance 
at 6 days (Figure 17B–D). 
TGF-β1 is a key molecule in the mesenchymal conversion of MCs. Accordingly, 
experiments blocking the TGFβ type I receptor were performed. Quantitative RT-PCR analysis 
revealed that the selective inhibitor GW788388 blocked the induction of Snail, collagen I and 
fibronectin mediated by TGF-β1- or SKOV-3-conditioned medium (Figure 18). 
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Figure 16. Conditioned medium from SKOV-3 cells induces MMT in vitro. 
(A) Treatment of HPMCs with conditioned media (CM) from SKOV-3 cells induces the 
acquisition of a spindle-like phenotype that is evident at 72(h and more pronounced at 6(days. 
The morphology alteration of HPMCs is similar to that observed in cells treated with TGF-β1 
plus IL-1β (T+I). Scale bars(=(100(µm. (B, C) The mesenchymal conversion of HPMCs treated 
with conditioned medium is verified at the molecular level by qRT–PCR analysis of recognized 
MMT markers. The expression of E-cadherin is repressed in HPMCs treated for 72(h with 
SKOV-3-derived conditioned medium when compared with control medium-treated HPMCs. 
On the contrary, the expression of Snail is upregulated in HPMCs treated with conditioned 
medium. (D–G) The expression of other MMT-associated markers including the matrix 
components fibronectin and collagen I, as well as the growth factors VEGF and TGF-β1, are 
also significantly up-regulated in HPMCs treated with conditioned medium. Bar graphics 
represent mean(±(SEM. Symbols represent the statistical differences between groups. FI, fold 
induction. 
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Figure 17. Conditioned medium from HT29 cells induces a MMT in vitro. 
(A) Conditioned medium (CM) obtained from the colorectal adenocarcinoma cell line HT29 
was applied for 6(days to HPMCs to induce MMT. The treatment induced the acquisition of a 
spindle-like morphology in HPMCs. Scale bars(=(100(µm. (B–D) MMT molecular 
reprogramming, including the repression of E-cadherin and the up-regulation of mesenchymal 
markers such as fibronectin and collagen-I, reach statistical significance at 6(days of exposure to 
HT29-conditioned medium. Bar graphics represent mean(±(SEM; symbols represent the 
statistical differences between groups. FI, fold induction; T+I, TGF-β1 plus IL-1β. 
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Figure 18. Blockade of TGF-β receptor I  inhibitor interferes with the MMT. 
HPMCs were treated for 72(h with TGF-β1 (1 ng/ml) or SKOV-3-conditioned medium (CM) in 
the presence or absence of 2 or 5(µm GW788388 (GW). (A, B) Quantitative RT–PCR shows 
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that GW788388 blocks the induction of fibronectin and collagen I mediated by TGF-β1 or 
SKOV-3-conditioned medium; (C) GW788388 also blocks the up-regulation of the MMT-
associated molecule Snail. Bar graphics represent mean(±(SEM. Symbols represent the 
statistical differences between groups. FI, fold induction. 
4. Mesenchymal conversion of MCs enhances the adhesion of tumour cells 
Adhesion experiments demonstrated that SKOV-3 cells had a significantly higher 
interaction capacity with mesenchymal-like HPMCs (stimulated with T+I) than with untreated 
HPMCs (Figure 19A, B). It was then investigated whether β1-integrins mediated the increased 
adhesion of tumour cells to HPMCs that were undergoing a MMT. Treatment of cells with the 
blocking anti-β1 antibody Lia1/2 disrupted both the basal adhesion of SKOV-3 cells to 
untreated HPMCs and the increased adhesion to transdifferentiated HPMCs. Conversely, 
treatment with the activating anti-β1 integrin antibody TS2/16 dramatically enhanced the 
adhesion of tumour cells to untreated HPMCs and to HPMCs T+I. Other blocking antibodies 
specific for the adhesion molecules VLA-1 (5E8D9) and β2-integrin (Lia3/2) did not affect the 
adhesion of tumour cells to HPMCs (Figure 19C). Our data demonstrated that the MMT 
promoted the adhesion of tumour cells and suggested that activated β1-integrin mediated, at 
least partially, the tumour cell–mesothelium interaction. 
To explore whether the enhanced adhesion of tumour cells to mesenchymal-like 
HPMCs was due to exposure of underlying matrix or to an increased cell–cell interaction, 
scanning electron microscopy imaging analysis was carried out. The images showed SKOV-3 
cells, maintaining a round-shaped morphology, laid on the monolayer of HPMCs with 
cobblestone features (Figure 19D). In contrast, SKOV-3 cells spread on transdifferentiated 
HPMCs, losing their round shape. Tumour cells emitted pseudopodial protrusions across the 
cytoplasmic extensions of mesenchymal-like HPMCs (Figure 19E). Detailed analysis of the 
images revealed that the enhanced adhesion of tumour cells was mostly due to increased cell–
cell interaction and not to the underlying matrix exposed through the intercellular spaces. 
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Figure 19. Tumour cells adhere mainly to the transdifferentiated MC monolayer through 
cell–cell interactions. 
(A) Representative images show CFSE-labelled SKOV-3 cells (green) adhered on DAPI-stained 
HPMC monolayers that have or have not been pretreated with T+I. Scale bars(=(100(µm. (B) 
Cancer cells adhere more efficiently to mesenchymal-like HPMCs than to HPMCs with 
epithelial morphology. Box plot graphic represents mean(±(SEM of number of adhered SKOV-3 
cells/field, 25th and 75th percentiles, median, minimum and maximum values. Differences are 
statistically significant (p = 0.04). (C) β1-integrins mediate the increased adhesion of tumour 
cells to transdifferentiated HPMCs. HPMCs were treated with the blocking anti-β1 antibody 
Lia1/2, activating anti-β1 antibody TS2/16, blocking antibodies specific for the adhesion 
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molecules VLA-1 (5E8D9) and β2-integrin (Lia3/2). Bar graphic represents mean(±(SEM of 
percentage of adhered cells, considering the number of cells prior to washing as 100%. Symbols 
represent the statistical differences between groups; T+I, TGF-β1 plus IL-1β. (D) High-
resolution images of co-cultures were obtained by scanning electron microscopy. SKOV-3 cells 
laid on a monolayer of HPMCs with epithelial-like morphology. Cancer cells adhered to control 
monolayers maintain a round-shaped morphology. (E) Transdifferentiated MC monolayers 
show a disorganized structure on which numerous cancer cells spread out and lose their round 
aspect. At high magnification, SKOV-3 cells display pseudopodial protrusions across the 
cytoplasmic extensions of mesenchymal-like HPMCs. Scale bars(=(10(µm. T+I, TGF-β1 plus 
IL-1β. 
5. MCs and tumour cells mutually stimulate their invasive capacity 
Next, it was assessed whether mesenchymal HPMCs could promote the invasion of 
tumour cells. SKOV-3 cells seeded on a collagen I matrix did not show invasive capacity. On 
the contrary, carcinoma cells seeded on matrix harbouring HPMCs with an epithelial-like 
phenotype showed an increase in their invasive capacity. This effect was much more evident 
when HPMCs with a mesenchymal phenotype were embedded in the matrix (Figure 20A, B). 
The number of invading SKOV-3 cells increased significantly (p=0.003) when mesenchymal 
HPMCs were present in the matrix, compared with embedded epithelial-like HPMCs (Figure 
20C). Histological analysis revealed that the MC monolayer was preserved in tumour-free 
regions but it was disrupted in areas with micrometastases, where CAFs expressing mesothelial 
markers could be observed (Figure 5C inset). These data suggested that tumour cells might, in 
turn, promote HPMCs to invade the stroma. In vitro invasion assays were performed to analyse 
the effect of carcinoma cells on the invasion capacity of HPMCs. SKOV-3 cells embedded in a 
collagen I matrix were able to attract the HPMCs from the monolayer into the matrix. In 
contrast, HPMCs seeded on collagen I matrix without cancer cells remained mainly as a 
monolayer (Figure 21A–C). The number of invading HPMCs showed a significant increase 
(p=0.03) when SKOV-3 cells were present in the matrix (Figure 21D). 
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Figure 20. Mesenchymal-like HPMCs strongly stimulate the invasive capacity of 
carcinoma cells. 
(A, B) Transverse projection and 3D reconstructions of confocal laser scanning microscopy 
show that SKOV-3 cells (red) seeded on a collagen I matrix do not invade after 5(days. In 
contrast, carcinoma cells seeded on matrix harbouring CFSE- and propidium iodide-labelled 
HPMCs (green(+(red), with either epithelial-like (HPMCs) or mesenchymal-like (HPMCs((T+I) 
phenotype, show a significant increase in invasive capacity. This effect is much more evident 
when HPMCs with a mesenchymal phenotype are embedded in the matrix. Scale bars = 
100(µm. (C) Quantification analyses of SKOV-3 invading cells were performed by subtracting 
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CFSE-labelled HPMCs (green) from the total propidium iodide-stained cells (red) that invaded 
the matrix. Thus, the invasion of SKOV-3 corresponds to red cells in the merge panel, since 
embedded HPMCs are yellow (green(+(red). Results show the percentage of invading SKOV-3 
cells in gels containing HPMCs versus gels containing HPMCs pretreated with T+I. Bar 
graphics represent mean(±(SEM; the difference is statistically significant (p = 0.003). T+I, TGF-
β1 plus IL-1β. 
!
Figure 21. Tumour cells embedded in the matrix induce MC invasion. 
(A) H&E sections of paraffin-embedded gels show the disruption of the MC monolayer when 
SKOV-3 cells are present in a collagen I matrix, mimicking a metastatic submesothelium. (B) 
Confocal images display transverse projections of CFSE- and propidium iodide-labelled SKOV-
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3 cells (green + red) embedded in a collagen I matrix. Carcinoma cells are able to attract 
HPMCs (red) from the monolayer into the matrix. However, HPMCs seeded on collagen I 
matrixes without cancer cells remain mainly as a monolayer. (C) Reconstructions in 3D of 
confocal laser scanning microscopy. (D) Quantification analyses of invading HPMCs were 
performed by subtracting CFSE-labelled SKOV-3 cells (green) from the total propidium iodide-
stained cells (red) that invaded the matrix. Thus, the invasion of HPMCs corresponds to red 
cells in the merge panel, since embedded SKOV-3 cells are yellow (green + red). Results 
show the percentage of invading HPMCs in gels containing SKOV-3 cells versus gels without 
tumour cells. Bar graphics represent mean ± SEM; the difference is statistically significant (p = 
0.03). Scale bars = 100 µm. 
6. Ascitic fluid-derived mesothelial cells undergo a mesothelial-to-mesenchymal 
transition 
Once it had been established that there is a mesenchymal conversion of MCs in the 
peritoneum and that the MMT played a role in the adhesion and invasion of cancer cells, the 
characterisation of MCs isolated from the ascitic fluid of ovarian cancer patients with peritoneal 
metastasis was performed. In culture, some ascitic fluid-derived MCs (AFMCs) had a 
fibroblast-like morphology, similar to that of HPMCs T+I (Figure 22A a). Positive 
immunofluorescence staining for calretinin confirmed the mesothelial cell type (Figure 22A b), 
and α-SMA staining indicated that AFMCs had converted into myofibroblasts (Figure 22A b). 
Analysis of conventional MMT-related markers by quantitative RT-PCR showed the expression 
of E-cadherin was repressed and, conversely, the expression of Snail, TGF-β1 and VEGF was 
induced in AFMCs compared to control HPMCs (Figure 22B a-d). The difference in these 
markers was significant, except for TGF-β1, where a tendency to a higher expression in AFMCs 
can be observed. This pattern is indicative of an in vivo MMT taking place in AFMCs. The 
expression of extracellular matrix (ECM) proteins was also considered. Although a tendency to 
a higher expression in AFMCs compared to controls was observed in the case of fibronectin 
(Figure 22B e), there were no differences for collagen I (Figure 22B f). These data suggest that 
AFMCs have converted into CAFs.  
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Figure 22. AFMCs undergo a MMT. 
(A) (a) Representative phase contrast microscopy images of HPMCs, HPMCs T+I and AFMCs 
in culture. Scale bar(=(100(µm. (b) Immunofluorescence staining for calretinin, confirming 
mesothelial cell type, and (c) α-SMA, indicating myofibroblast conversion of AFMCs. Scale 
bars(=(25(µm. (B) Transcript levels of MMT markers analysed by real time qRT-PCR in 
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HPMCs (n=8), HPMCs T+I (n=8) and AFMCs (n=5). (a-d) E-cadherin expression is repressed 
and, conversely, the expression of Snail, TGF-β1 and VEGF is induced in AFMCs and HPMCs 
T+I compared to control HPMCs. All were significant except for TGF-β1. (e, f) The expression 
of other MMT markers, collagen and fibronectin, is not significantly different between AFMCs 
and controls. Bar graphics represent mean ± SEM. Symbols represent the statistical 
differences between groups. A.U., arbitrary units; T+I, TGF-β1 plus IL-1β. 
7. Ascitic fluid-derived mesothelial cells promote tumour growth of ovarian cancer 
cells in a subcutaneous xenograft mouse model 
In order to study the role of transdifferentiated AFMCs in tumour growth, a 
subcutaneous xenograft mouse model was used. Although SKOV-3-luciferase cells are efficient 
in establishing peritoneal metastases, a preliminary assay showed that cancer cells alone are 
unable to grow when subcutaneously inoculated (Figure 23A). The differential behaviour of 
cancer cells in these two different microenvironments suggests that MC-derived CAFs may be 
key players in peritoneal metastasis. Therefore, SKOV-3-luciferase cells were subcutaneously 
co-inoculated with control HPMCs in the left flank, and with either HPMCs T+I (Figure 23B) 
or AFMCs (Figure 23C) in the right flank. Bioluminiscence monitoring showed that tumour 
growth was significantly increased in tumours in the right flank, where MCs that had undergone 
a MMT had been co-injected. 
8. Identification of a mesothelial-to-mesenchymal gene signature in ascitic fluid-
derived mesothelial cells 
RNA-sequencing analysis was carried out on control HPMCs and AFMCs. Expression 
data for each gene within each sample was used to create a heatmap for cluster classification, 
which revealed a clear separation between HPMCs and AFMCs (Figure 24A). Ensembl ID of 
differentially-expressed genes, i.e., genes with a q-value < 0.05 and a fold change higher than 
2, were submitted to IPA® for functional annotation, identification of upstream regulators, and 
mapping to canonical pathways. 
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Figure 23. AFMCs favour tumour progression in a subcutaneous xenograft mouse model. 
(A) Preliminary assay of subcutaneous inoculation of SKOV-3-luciferase cells in left flank and 
co-inoculation with AFMCs in the right flank, indicating SKOV-3 cells alone do not grow 
subcutaneously. (B, C) SKOV-3-luciferase cells were co-inoculated with control HPMCs in the 
left flank of nude mice, and with either T+I HPMCs (B) (n=8) or AFMCs (C) (n=6) in the right 
flank. Bioluminiscence monitoring showed that tumour growth was significantly increased in 
tumours in the right flank, where HPMCs that had undergone a MMT had been used. Graphs 
represent mean average radiance of SKOV-3-luciferase cells ± SEM. Symbols represent the 
statistical differences between groups. T+I, TGF-β1 plus IL-1β. 
The analysis revealed 1997 upregulated genes and 1646 downregulated genes in 
AFMCs relative to their expression in control HPMCs. A summary of the top 100 up-regulated 
and top 100 down-regulated genes in AFMCs, along with the fold change for each gene is 
presented in Supplementary Tables 1 and 2, respectively. Among the canonical pathways that 
were significantly differentially regulated, many were directly related to MMT: hepatic stellate 
cell activation, regulation of EMT pathway, caveolar-mediated endocytosis signalling, vitamin 
D receptor/retinoid X receptor (VDR/RXR) activation, inhibition of angiogenesis by 
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thrombospondin 1 (TSP1), tight junction signalling, and signalling pathways for integrin-linked 
kinase (ILK), TGF-β, HGF, thrombin, peroxisome proliferator-activated receptor (PPAR), p38 
and NF-κB. Other pathways are related to steps involved in tumour progression (integrin 
signalling, inhibition of matrix metalloproteases) or have been associated to ovarian cancer 
(signalling pathways for IL-6, IL-8 and IL-10) (Figure 24B). Upstream regulators represented in 
our dataset were identified and, interestingly, the top 3 (TNF, TGF-β1 and IL-1β) are known 
inducers of MMT (Figure 24C).  
!
Figure 24. RNA-seq analysis of AFMCs. 
(A) Heatmap representing the differentially expressed genes in HPMCs and AFMCs. (B) 
Significantly differentially regulated canonical pathways analysed by IPA. The y-axis indicates 
the statistical significance, calculated using the Benjamini-Hochberg correction (-log(p-value) = 
1.3). The yellow threshold line represents this cutoff. (C) Top 3 upstream regulators in the 
dataset. P-value of overlap (p < 0.05) represents the statistical significance of genes in the 
dataset to overlap with the list of downstream targets of a given regulator. The activation z-
score (z-score ≥ |2|) infers the activation state of the transcriptional regulator based on published 
findings. 
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9. Mesothelial-to-mesenchymal transition via TGF-β1 in the peritoneum renders 
peritoneum more susceptible to metastasis 
Previously, MCs that had undergone a MMT were shown to promote an increased 
invasion and attachment of cancer cells. Based on this, it was hypothesized that a peritoneum 
where a MMT had taken place could be more receptive to metastasis. Given that TGF-β1 is a 
key MMT inducer and also appeared as a key regulator in the RNA-seq data of AFMCs, it was 
of interest to study its role in intraperitoneal tumour progression. Thus, the peritoneum of mice 
was pre-conditioned, in order to induce an early MMT, by overexpressing TGF-β1 with i.p. 
adenoviral delivery, followed by SKOV-3-luciferase cell i.p. inoculation. Then, mice were 
monitored for 41 days with via in vivo bioluminiscence imaging. Tumour growth and 
progression were significantly higher in mice whose peritoneum had undergone a MMT, 
compared to those where a control adenovirus—and, hence, no induced MMT—had been used 
(Figure 25). 
!
Figure 25. Overexpression of TGF-β in the peritoneum supports tumour progression. 
In vivo monitoring of SKOV-3-luciferase cells in nude mice pre-conditioned with adenovirus 
encoding for TGF-β1 or control. Graph represents mean average radiance of SKOV-3-luciferase 
cells ± SEM. Symbols represent the statistical differences between groups. n=6 per group. 
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Although ovarian cancer cells secrete a high concentration of TGF-β1, many other 
cytokines and factors that are also present in the ascitic fluid could have an effect on the 
peritoneum. In a preliminary experiment, it was observed that pre-conditioning the peritoneum 
of mice for 2 days with conditioned medium from SKOV-3 cells decreased E-cadherin 
expression in the mesothelial monolayer, indicating that an early MMT had taken place (Figure 
26A). In order to study the role of TGF-β1 in conditioned medium in the context of metastasis, 
mice were pre-treated with a TGF-β1 receptor I inhibitor (GW788388) and then with 
conditioned medium from SKOV-3 cells, followed by SKOV-3-luciferase cell i.p. delivery. 
Monitoring of tumour progression for 41 days by in vivo bioluminiscence imaging, showed that 
tumour growth was significantly higher in mice where an early MMT had been induced with 
cancer cell medium (Figure 26B). Interestingly, when the TGF-β1 receptor I was inhibited and 
cancer cell medium was used, tumour growth was maintained at levels comparable to those of 
mice with no induced MMT (control medium). These results suggest that, despite other 
cytokines also having possible roles in tumour growth and metastasis, blocking the TGF-β1 
pathway is sufficient to see a significant and dramatic change in tumour progression.  
10. Crosstalk between mesothelial-derived carcinoma-associated fibroblasts and 
cancer cells takes place via TGF-β1/pSmad3 pathway 
MC-derived CAFs and cancer cells produce large amounts of TGF-β1. It has been 
described that TGF-β1 can induce a MMT via Smad-dependent and/or Smad-independent 
pathways. On this note, Smad3 is an important downstream mediator in the Smad-dependent 
signalling of TGF-β1 and, once phosphorylated, activates gene transcription in the nucleus. 
However, the response to TGF-β1 through Smad3 has not been analysed in MC-derived CAFs. 
Thus, double immunofluorescence staining for α-SMA and phosphorylated Smad3 (pSmad3) 
was carried out in MC cultures. Our results showed that control HPMCs were negative for both 
markers (Figure 27A a). However, nuclear expression of pSmad3 was observed in α-SMA-
positive HPMCs T+I and AFMCs (Figure 27A b, c). 
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Figure 26. Blockade of  TGF-β receptor I blocks the tumour growth induced by cancer cell 
media. 
(A) Immunohistochemistry staining for E-cadherin (ECD) on the peritoneum of a mouse 
sacrificed 2 days after being pre-conditioned with cancer cell medium (CM) shows early MMT. 
Scale bars = 25 µm. (B) In vivo monitoring of SKOV-3-luciferase cells in nude mice pre-
conditioned with CM control medium together with the TGF-β receptor I inhibitor GW788388 
(GW) or vehicle. n=6 per group. Graphs represent mean average radiance of SKOV-3-luciferase 
cells ± SEM. Symbols represent the statistical differences between groups.  
Results!!!
!
Quantification of the percentage of pSmad3-positive nuclei revealed a significant 
increase in HPMCs T+I and AFMCs (p = 0.0043, p = 0.0002, respectively) (Figure 27B). 
!
Figure 27. TGF-β1/Smad3 pathway is activated in AFMCs, inducing a MMT. 
(A) Double immunofluorescence staining for α-SMA and pSmad3 in HPMCs (a), HPMCs T+I 
(b) and AFMCs (c) indicates a MMT has taken place through Smad-dependent TGF-β1 
pathway activation in transdifferentiated AFMCs. (d) Percentage of pSmad3-positive nuclei. 
Scale bars(=(25(µm. (B) Quantification of percentage of pSmad3-positive nuclei. Box plot 
graphic depicts 25th and 75th percentiles, median, minimum and maximum values; symbols 
represent the statistical differences between groups. T+I, TGF-β1 plus IL-1β. 
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Knowing that the TGF-β1 route was activated in both transdifferentiated HPMCs and 
AFMCs, its activation state was verified in ovarian cancer cells. HPMCs and SKOV-3 cells 
were treated with TGF-β1 for 1 and 6 hours. As expected, by immunofluorescence pSmad3 is 
shown to be translocated to the nucleus in HPMCs (Figure 28A, B, E, F). Surprisingly, in the 
cases in which ovarian cancer cells were exposed to TGF-β1, pSmad3 remained cytoplasmic 
(Figure 28C, D, G, H). These results suggest that the TGF-β1/Smad3 pathway could be 
truncated in ovarian cancer cells. 
!
Figure 28. TGF-β1/Smad3 pathway is truncated in SKOV-3 cells. 
Treatment of SKOV-3 cells and HPMCs with TGF-β1 (4 ng/ml) for 1 and 6 hours. 
Inmunofluorescence images show that, upon TGF-β1 treatment, pSmad3 translocates to the 
nucleus in HPMCs (A, B, E, F), and remains cytoplasmic in ovarian cancer cells (C, D, G, H). 
Scale bars(=(25(µm. 
In order to corroborate the nuclear localization of pSmad3 in peritoneal CAFs, serial 
sections of mouse tissues were analysed by immunohistochemistry, staining for α-SMA and 
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pSmad3. The peritoneum of non-tumour-bearing mice showed a preserved mesothelial 
monolayer that was negative for both markers (Figure 29A, B). However, in tumour-bearing 
mice, the peritoneum was positive for pSmad3 but still negative for α-SMA in areas distant to 
the tumour microimplants (Figure 29C, D). Interestingly, in areas close to the micrometastasis, 
positive α-SMA and nuclear pSmad3 staining are overlapped in the submesothelial fibrotic zone 
(Figure 29E, F). In tumour areas, an accumulation of CAFs (α-SMA positive) expressing 
nuclear pSmad3 was observed surrounding cancer cells where, similarly to the previous in vitro 
assay, pSmad3 remained cytoplasmic (Figure 29G, H). 
!
Figure 29. Immunohistochemical analysis of mouse peritoneal tissues. 
Staining of serial sections was performed for α-SMA and pSmad3. (A, B) Peritoneum of a 
control mouse showing a preserved mesothelium and negative expression for both markers. (C-
H) Same sample from a mouse with ovarian cancer implants in the peritoneum: (C, D) 
Preserved and nuclear pSmad3-positive mesothelial monolayer in an area distant to the tumour 
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cells. (E, F) Submesothelial CAFs expressing α-SMA are accumulated in an area closer to the 
tumour site and overlap with nuclear pSmad3-positive cells. (G, H) Peritoneal metastasis where 
ovarian cancer cells show cytoplasmic expression of pSmad3, and adjacent CAFs (α-SMA-
positive) express nuclear pSmad3. Scale bars(=(50(µm (A-F) and 25(µm (G, H). Arrows indicate 
CAFs in the proximity of tumour implants expressing nuclear pSmad3. Insets show higher 
magnifications of the delimited areas. T, tumour. 
The differential localisation of pSmad3 in MC-derived CAFs and cancer cells was also 
analysed by immunohistochemistry in serial sections of peritoneal implant biopsies from 
patients with ovarian cancer, staining for calretinin, α-SMA and pSmad3. The peritoneum of 
control donors showed a calretinin-positive preserved mesothelial monolayer with no staining 
for α-SMA or pSmad3 (Figure 30A-C). However, in ovarian cancer patients, preserved 
mesothelial areas distant to tumour cells showed nuclear expression of pSmad3, indicating that 
the TGF-β1 pathway had been activated (Figure 30D-F). It can be hypothesized that an early-
stage MMT is taking place in these cells, but an invasive phenotype has not been acquired yet, 
hence the monolayer structure and lack of α-SMA expression. In the tumour stroma, there was 
an accumulation of cells with a fibroblastic phenotype. Some of these cells with spindle-like 
morphology are triple positive for calretinin, α-SMA and nuclear pSmad3, confirming 
mesothelial cells have undergone a MMT, invaded the stroma, and transdifferentiated into 
CAFs (Figure 30G-I). Ovarian cancer peritoneal nodules from the same patient were pSmad3-
negative (Figure 30I) or showed pSmad3 staining limited to the cytoplasmic compartment, in 
contrast with the surrounding MC-derived CAFs presenting nuclear pSmad3 expression (Figure 
30J-L). 
11. Lentiviral knockdown of Smad3 in the peritoneum reduces metastasis 
Having observed that the TGF-β1/pSmad3 pathway is relevant in the communication 
between ovarian cancer cells and HPMCs, lentiviral particles containing Smad3 shRNA were 
administered to mice in order to knock down its expression, followed by SKOV-3-luciferase 
cell i.p. inoculation. Mice were then monitored for 41 days via in vivo bioluminiscence imaging. 
Tumour growth and progression were significantly reduced in mice whose peritoneum had been 
knocked down of Smad3 expression (Figure 16). 
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Figure 30. Immunohistochemical analysis of human peritoneal implants of ovarian cancer. 
Staining of serial sections was performed for calretinin, α-SMA and pSmad3. (A-C) Peritoneum 
of a control donor showing a preserved mesothelium and negative expression for both markers. 
(D-L) Same sample of ovarian cancer implant in the peritoneum. (D-F) Preserved mesothelial 
monolayer (calretinin-positive) in an area distant to the tumour cells, positive for nuclear 
pSmad3. (G-I) Submesothelial tumour implant showing surrounding stromal CAFs (α-SMA-
positive) derived from MCs (calretinin-positive) and expressing nuclear pSmad3. (J,K) 
Micrometastasis, showing ovarian cancer cells with cytoplasmic expression of pSmad3, and -
MC-derived CAFs surrounding the tumour and expressing nuclear pSmad3. (L) Higher 
magnification of  the cytoplasmic pSmad3 staining in tumour cells. Scale bars(=(25(µm (A-C, G-
K), and 50(µm (D-F). Arrows indicate MC-derived CAFs, expressing nuclear pSmad3 in the 
proximity of tumour implants. Insets show higher magnifications of the delimited areas. T, 
tumour. 
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Figure 31. Lentiviral knockdown of Smad3 reduces tumour progression. 
In vivo monitoring of SKOV-3-luciferase cells in nude mice pre-conditioned with lentiviral 
particles producing Smad3 shRNA or control. Graph represents mean average radiance of 
SKOV-3-luciferase cells ± SEM. Symbols represent the statistical differences between groups. 
n=9 per group. 
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CAFs deriving from various sources play an important role in facilitating tumour 
progression. In this work it is shown, for the first time, that in peritoneal implants of abdominal 
cancers, such as ovarian and colorectal, a proportion of CAFs derives from MCs via a MMT 
that is induced by cancer cells. The mesenchymal conversion of MCs favours the adhesion and 
invasion of metastasizing tumour cells and promotes the growth of secondary tumour implants. 
The MMT has been widely studied in the context of peritoneal dialysis, and has been suggested 
to play an important role in modifying the peritoneal structure, associated with fibrosis and 
angiogenesis (Aroeira et al. 2007; López-Cabrera 2014). A population of CAFs was observed to 
express several mesothelial markers: calretinin, WT1, mesothelin, and cytokeratin. The 
presence of CAFs expressing these mesothelial markers, in both human biopsies and mouse 
peritoneal samples, indicates that a subpopulation of CAFs originates from MCs during 
peritoneal tumour dissemination. Additionally, there is a marked fibro-proliferative response 
and increased angiogenesis at the places of tumour implants, where MC-derived CAFs 
accumulate. These results suggest that MMT plays important roles in transforming the tumour 
stroma at the secondary site in the peritoneum. When metastasizing to the peritoneum, cancer 
cells can attach to the MC monolayer or to the exposed submesothelial matrix. It has been 
proposed that tumour cells prefer the ECM for first attachment, predominantly binding to 
“milky spots” during the initial stages of peritoneal metastasis. In this regard, in vitro adhesion 
experiments demonstrate that cancer cells adhere better to mesenchymal than to epithelial-like 
MC monolayers. This is in agreement with other reports, where cancer cell adhesion was 
increased to mesothelial cells that had undergone a MMT (Jiang et al. 2013), or expressed the 
CAF marker FAP (Miao et al. 2014). Similarly, treatment of MCs with TNF-α induces a 
fibroblast-like conversion (Zhu et al. 2002) which increases the adhesion to cancer cells (Yu et 
al. 2010). In contrast to the “milky spot” preference regarded until now, scanning electron 
microscopy analysis suggested that the enhanced adhesion of tumour cells to mesenchymal 
MCs is due to an increased cell–cell interaction and not to a mere exposure of the underlying 
matrix. Hence, the MMT could play a role in conferring an advantage on metastatic cells for 
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attachment to the peritoneal membrane. The use of different β1 inhibitors indicated that this 
cancer cell–mesothelium interaction is mediated, at least in part, by β1-integrins, which is in 
agreement with reports by others (Takatsuki et al. 2004; Watanabe et al. 2012; Chen et al. 
2015). However, other adhesion molecules have also been described to be participating in this 
interaction; although, their role throughout the mesenchymal conversion of MCs would require 
further analysis (Casey and Skubitz 2000; Ziprin et al. 2003; Rump et al. 2004; Alkhamesi et al. 
2005; Ksiazek et al. 2010; Wagner et al. 2011) 
 
Histological analysis shows that MC-derived CAFs accumulate in areas with 
micrometastases, coinciding also with prominent new vessel formation, but not in tumour-free 
regions, suggesting that tumour cells promote the invasion of adjacent MCs. On this note, MCs 
have been reported to create the invasion front of cancer cells (Satoyoshi et al. 2015a). 
Interestingly, in areas distant to micrometastasis, where the mesothelial monolayer is preserved, 
the nuclear localisation of pSmad3 suggests a mesenchymal conversion may be underway, but 
an invasive phenotype has not been acquired yet, which can be explained by the lack of α-SMA 
expression. The in vitro invasion assays demonstrate that carcinoma cells embedded in the 
matrix enhance the invasive capacity of MCs, which could be a consequence of the MMT. In 
this context, it is demonstrated that MCs with a mesenchymal phenotype markedly stimulate the 
invasion of ovarian carcinoma SKOV-3 cells, more so than MCs with an epithelial-like 
phenotype. The pro-invasive capacity acquired by mesenchymal MCs is in accordance with 
CAFs’ known properties (Karagiannis et al. 2012). Thus, these results suggest that 
mesenchymal MCs and carcinoma cells establish a feed-forward cycle by mutually stimulating 
their invasiveness. This is in agreement with other reports of cancer cells stimulating MC 
invasiveness (Nakamura et al. 2015) and vice versa (Ren et al. 2006; Heyman et al. 2010; 
Kenny et al. 2014). 
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Given that the mesenchymal conversion of peritoneal MCs exerted an effect on ovarian 
cancer cells, it was of interest to study and characterise the MCs suspended in the ascitic fluid of 
ovarian cancer patients. These AFMCs were expressing the myofibroblast/CAF marker α-SMA, 
indicating they had undergone a MMT. Additionally, the TGF-β downstream effector pSmad3 
was expressed in the nucleus, where it can modify gene transcription. It is also interesting to 
note that, in RT-PCR data, the transcription factor Snail is induced, which leads to a decrease in 
the E-cadherin levels. The angiogenesis-promoting factor VEGF is overexpressed; however, the 
ECM proteins collagen I and fibronectin were not significantly affected. RNA-seq analysis 
provided a more detailed pattern of the changes taking place in AFMCs. A sizeable proportion 
of the pathways that were significantly differentially regulated was directly associated to MMT 
(TGF-β signalling) or its consequences (loss of tight junctions, angiogenesis). The most 
differentially regulated pathway regards the hepatic stellate cell activation which, interestingly, 
MCs have been reported to convert into through a MMT (Li et al. 2013). Other molecules in 
these pathways have relevant roles in the MMT context: ILK mediates TGF-β1-induced EMT 
and myofibroblast differentiation (Li et al. 2003; Vi et al. 2010); Caveolin-1 is implicated in the 
internalization of TGF-β receptor type I, blocks the phosphorylation of Smad2, and its 
deficiency induces MMT (Razani et al. 2001; Strippoli et al. 2015); vitamin D regulates the 
TGF-β-induced EMT (Pervin et al. 2013; Fischer and Agrawal 2014; Li et al. 2015; Larriba and 
de Herreros 2016); a PPAR agonist (rosiglitazone) protects the peritoneal membrane in vivo 
(Sandoval et al. 2010; Bunt et al. 2013); thrombin has been shown to promote cancer cell 
invasion by inducing EMT (Zhong et al. 2013) and the expression of β1-integrin and MMP-9 
(Radjabi et al. 2008); p38 and NF-κB regulate EMT (Strippoli et al. 2008; 2010; 2012); and, 
recently, HGF secreted by ovarian cancer cells has been implicated in inducing a MMT and 
favouring invasion of MCs (Nakamura et al. 2015). During MMT, there is an increased 
angiogenesis and upregulation of MMPs (López-Cabrera 2014). In the RNA-seq data, two 
pathways that inhibit these processes appear as differentially regulated. However, this does not 
necessarily implicate that these processes are indeed inhibited, e.g. molecules implicated in the 
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inhibition of angiogenesis have a different regulation in AFMCs, which may lead to a blockade 
of this inhibiting pathway and, thus, promotion of angiogenesis. Supporting this, pro-angiogenic 
factors such as VEGF-A, VEGF-B, FGF-2, PDGF-A and PDGF-B, and MMPs 1, 2, 3, 7 and 9 
appear upregulated in AFMCs in the RNA-seq data. Other pathways that are differentially 
regulated include signalling of various molecules present in the ascitic fluid and associated with 
ovarian cancer progression and poor prognosis: IL-6, IL-8 and IL-10 (Moradi et al. 1993; Santin 
et al. 2001; Mustea et al. 2006; Giuntoli et al. 2009; Lane et al. 2011; Matte et al. 2012). In this 
context, only IL-6 has been reported to be highly produced by HPMCs (Offner et al. 1995) 
compared to ovarian cancer cells. These data show, for the first time, that AFMCs secrete an 
array of inflammatory cytokines that will affect cancer progression. Overall, these pathways 
provide an overview of the changes taking place in AFMCs, and allow to conclude that these 
cells have undergone a MMT. The mesenchymal conversion will, in turn, transform the 
environment, rendering it more favourable for tumour progression by continuing to promote a 
MMT in an inflammatory and immunosuppressive context. On this note, the inflammatory 
cytokines IL-1β and TNF-α have been reported to work synergistically with TGF-β1 in 
upregulating VEGF (Catar et al. 2013) and IL-6 production in MCs (Offner et al. 1995). The 
fact that, in the RNA-seq data, IL-1β and TNF-α have a higher activation z-score than TGF-β1 
as upstream regulators, could point to the MMT taking place in AFMCs as a link between the 
inflammatory environment present in the ascitic fluid and the induction of angiogenesis. 
However, a larger sample size of AFMCs is necessary to conclude these differential MMT 
outcomes. Patient heterogeneity is very high, which could also explain why the ECM proteins 
do not appear as upregulated in the RT-PCR data. 
In agreement with the MMT they have undergone, when co-injected with ovarian 
cancer cells, AFMCs favoured tumour growth in a subcutaneous xenograft mouse model, 
compared to control HPMCs with no MMT, indicating this transition plays a role in tumour 
progression. 
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TGF-β1 is a key molecule controlling MMT and peritoneal fibrosis (López-Cabrera 
2014) and, given that the MMT is driving the transformation of AFMCs, it was speculated that 
targeting the TGF-β1 pathway could interfere with the accumulation of CAFs. An in vivo assay 
of overexpression of TGF-β1 by adenoviral delivery indicated tumour progression was owed, at 
least partially, to TGF-β1. Previously, in vitro blockade of the TGF-β1 receptor was shown to 
prevent the mesenchymal conversion of MCs treated with conditioned medium from SKOV-3 
cells. Further confirmation was attained when blocking this receptor in vivo translated into a 
dramatic decrease in tumour growth. These results are supported by reports of in vivo TGF-β1 
blockade reducing peritoneal metastasis and improving survival in mice (Yamamura et al. 2011; 
Miao et al. 2013). The Smad-dependent pathway was considered to be activated in AFMCs, 
based on the nuclear localisation of pSmad3, a necessary step for the following transcriptional 
regulation (Derynck and Zhang 2003). Interestingly, biopsies of ovarian cancer implants in the 
peritoneum showed a differential localisation of pSmad3 between cancer cells and the MC-
derived CAFs that surround them, being cytoplasmic in the former, and nuclear in the latter. 
Despite SKOV-3 cells producing high amounts of TGF-β1 (measurement in their conditioned 
medium was 1141.6 ± 169.3 pg/ml versus 369.4 ± 27.2 pg/ml in HT-29 cells), the Smad-
dependent pathway was truncated in these cells: pSmad3 remained in the cytoplasm, unable to 
selectively activate or repress gene transcription in the nucleus, whereas in transdifferentiated 
MCs translocation was observable after 1 hour. Finally, knocking down Smad3 expression in 
mice resulted in reduced intraperitoneal tumour growth, indicating the Smad-dependent 
pathway is relevant in vivo. 
 
All of these data point to the MMT being a key player in the initiation and progression 
of peritoneal metastasis, which is the result of a multi-directional communication between 
cancer cells, MCs and CAFs. Cancer cells trigger the conversion of MCs into CAFs via a MMT, 
creating a suitable metastatic niche that renders the peritoneum more receptive for further 
metastatic implants, promotes cancer cell adhesion to and invasion through the peritoneum, and 
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facilitates tumour growth. MC-derived CAFs accumulate in the submesothelial compact zone, 
providing the tumour with the adequate blood support, ECM components and/or proliferating 
signals to progress to advanced stages (Figure 32). 
 
Figure 32. Model for transformation of the pre-metastatic niche by mesothelial-to-
mesenchymal transition in the peritoneum. 
(1) Cancer cells at the primary site secrete an array of exosomes, cytokines, chemokines and 
growth factors that accumulate in the ascitic fluid. Some of these molecules, such as 
transforming growth factor-beta1 (TGF-β1) or hepatocyte growth factor (HGF), induce changes 
in the mesothelial cells (MCs), triggering a mesothelial-to-mesenchymal transition (MMT), 
through which they lose apico-basal polarity and cell-cell adhesion, and acquire myofibroblastic 
properties. (2) Cancer cells adhere via β1 integrins to the MCs that line the peritoneum. This 
adhesion is increased when a MMT has taken place. (3) In later stages of MMT, MCs have 
converted into carcinoma-associated fibroblasts (CAFs) that represent the invasion front into the 
stroma, followed by cancer cells. (4) After invading, MC-derived CAFs accumulate in the 
peritoneal stroma. (5) CAFs produce factors that affect peritoneal implant progression: they 
induce angiogenesis via secretion of VEGF, among other factors; they transform the 
extracellular matrix (ECM) by producing collagen, fibronectin and other structural proteins, and 
they remodel the ECM via matrix metalloproteinases (MMPs); they also stimulate proliferation 
of cancer cells. (6) The metastatic niche in the peritoneum is created as a result of the clearance 
of the MC monolayer, myofibroblast conversion of MCs, invasion of MCs and cancer cells, 
accumulation of CAFs, increased vascularization, ECM remodelling and proliferation of cancer 
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cells. (7) Cancer cells in the new site, together with CAFs, will continue to produce factors that 
modify the stroma and induce changes in both cancer cells and MCs, thereby creating a positive 
feedback loop. Modified from A Rynne-Vidal et al., Cancers 2015. 
Mesothelial-to-mesenchymal transition as a potential therapeutic target in 
peritoneal metastasis.!
CAFs’ proven tumour-promoting capacities have raised interest in exploiting them as 
drug targets for anticancer therapy (Micke and Ostman 2005). The MMT that drives the 
conversion of MCs into CAFs points to a possible alternative target in the treatment of 
metastases that disseminate via the peritoneum, since this process can be modulated. 
Therapeutic strategies could be designed towards avoiding the accumulation of mesothelial-
derived CAFs in the compact zone. This could be achieved by targeting the MMT-inducing 
stimuli in the peritoneal cavity, by blocking or reverting the MMT itself, and/or by treating the 
MMT-associated effects, such as tumour cell adhesion and invasion, ECM accumulation or 
synthesis of pro-angiogenic factors (Figure 33). 
!
Figure 33. Targets for therapeutic strategies in the treatment of peritoneal metastasis. 
Different steps can be targeted, such as the MMT-promoting stimuli, the MMT itself, or the 
adhesion, invasion, angiogenesis and ECM remodelling associated with it. Abs, antibodies. 
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One approach would be the use of pharmacological agents that preserve the 
mesothelium against several stimuli. The MMT can result from molecular inflammatory signals 
associated with the intraperitoneal ascitic environment, and previous studies of MMT in 
peritoneal dialysis have demonstrated that using pharmacological agents (celecoxib, 
rosiglitazone) that target inflammation can preserve the peritoneal membrane. In this context, 
celecoxib is a potent anti-inflammatory drug whose mechanism of action is based on the 
inhibition of cyclooxygenase (COX)-2, which is expressed at high levels by MCs that undergo 
MMT. COX-2 has been widely implicated in inflammatory responses, as well as in fibrotic and 
angiogenic processes in animal peritoneal dialysis models (Aroeira et al. 2009; Fabbrini et al. 
2009). Interestingly, expression of COX-2 is also elevated in tumour cells of colorectal and 
ovarian carcinomas (Menczer 2009; Rizzo 2011). Multiple clinical studies show the 
effectiveness of specific inhibitors of COX-2 in preventing or delaying re-occurrence of cancer, 
including metastases, in high risk patients (Arber et al. 2006; Baron et al. 2006; Solomon et al. 
2006; Midgley et al. 2010)., Rosiglitazone is an activating agonist of the inflammation regulator 
PPAR-γ whose use in vivo protects the peritoneal membrane in the context of peritoneal dialysis 
(Sandoval et al. 2010) and, combined with gemcitabine, reduces peritoneal metastasis, TGF-β 
production and cancer cell invasion (Bunt et al. 2013). On a separate note, vitamin D also has a 
role in immune regulation, and an activator (paricalcitol) of its receptor VDR has been shown to 
protect the peritoneal membrane, reduce fibrosis and attenuate the TGF-β-induced EMT in 
peritoneal dialysis (González-Mateo et al. 2014; Kang et al. 2014). Finally, in an inflammatory 
environment, the components of the renin-angiotensin-aldosterone system (RAAS) are 
upregulated in mesothelial cells; and blockade of this system has proven to protect the 
peritoneal membrane (Duman et al. 2004; Nessim et al. 2010). 
 
Another therapeutic approach could be directed to interfere with or modify the MMT. 
Regarding this idea, TGF-β1 is a master molecule in the induction of MMT and is highly 
accumulated in malignant ascitic fluids. Our data demonstrate that interfering with the TGF-β1 
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pathway, both in vitro and in vivo, blocks the conversion of MCs into CAFs and diminishes 
tumour growth and metastasis. Also, in vivo experiments showed that using a TGF-β1 blocking 
agent prevented peritoneal dissemination of gastric cancer cells by preserving the mesothelial 
monolayer structure (Miao et al. 2013). Although further studies are needed in this regard, it 
should be considered that agents directly blocking TGF-β1 cannot be easily employed in the 
clinical practice, at least for long-term treatments, because TGF-β1 has important modulating 
functions of the immune and inflammatory responses (Wang et al. 2010; Yoshimura et al. 
2010). In the present work, the mesenchymal conversion of MCs is reported to be taking place, 
at least partially, in a TGF-β1 Smad-dependent manner, although further downstream studies of 
this signalling pathway in MMT would provide more specific strategies for the preservation of 
peritoneal membrane with fewer side effects. In this context, the use of bone morphogenetic 
protein (BMP)-7 (an endogenous negative regulator of this process) has been shown to 
block/reverse MMT in vitro, ex vivo and in vivo, reducing fibrosis, angiogenesis, invasion and 
the acquisition of a mesenchymal phenotype by MCs (Vargha et al. 2006; Loureiro et al. 2010). 
Further, receptor antagonists (bosentan and macitentan) of endothelin-1 (ET-1), a TGF-β1 
transcriptional target, attenuated the MMT, fibrosis and angiogenesis induced by peritoneal 
dialysis (Busnadiego et al. 2015). Additionally, the TGF-β1 Smad-independent signalling 
pathways play a role in MMT, and prevention/reversion has been attained by targeting TAK-1 
(Strippoli et al. 2012), ERKs-1/2, and NF-κB (Strippoli et al. 2008; 2010; Jang et al. 2012). 
Further characterization of the involvement of these molecules in peritoneal metastasis could 
provide a wider range of possible molecular targets. On a related note, the recent description of 
HGF as an inducer of MMT in peritoneal metastasis could also open new therapeutic strategies 
focused on this signalling pathway. Regarding this idea, in vitro experiments have shown that 
the use of blocking antibodies against HGF, and inhibitors of HGF receptor (HGFR) and 
epidermal growth factor receptor (EGFR) block the migration of HPMCs (Matte et al. 2014b) 
and ovarian cancer cells (Sowter et al. 1999). Finally, tamoxifen is a synthetic modulator of the 
estrogen receptor that is known to act in peritoneal tissue. Its efficacy in preserving the 
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peritoneal structure was tested in a mouse model of peritoneal dialysis, where it reduced 
peritoneal thickness, angiogenesis and invasion of the compact zone by transdifferentiated MCs 
(Loureiro et al. 2013). With regard to ovarian cancer, hormone treatment with tamoxifen is 
often used in conjunction with chemotherapy and other therapies (Serkies et al. 2013).  
 
Targeting adhesion of cancer cells to the mesothelium could also be considered as a 
therapeutic strategy for peritoneal metastasis, given that blocking antibodies or siRNA directed 
against either ICAM-1 (Ranieri et al. 2013), VCAM-1 (Slack-Davis et al. 2009), fibronectin 
(Kenny et al. 2008) or their integrin ligands significantly decreased the adhesion and invasion of 
ovarian cancer cells through the MC monolayer, and dramatically reduced metastases in a 
mouse model (Kenny et al. 2014). The use of blocking antibodies or siRNA against α5 or β1 
integrins have shown significantly reduced adhesion, invasion, tumour burden and peritoneal 
metastasis (Sawada et al. 2008; Mitra et al. 2011; Watanabe et al. 2012; Kenny et al. 2014). On 
this note, the angiogenesis inhibitor endostatin targets the α5β1 integrin, and its use prevented 
the attachment of cancer cells to the mesothelium (Yokoyama et al. 2007). Interestingly, it has 
been reported that the oxidative stress that accompanies senescent MCs may facilitate the 
adhesion and dissemination of cancer cells; and the use of an antioxidant (PBN) significantly 
reduced this attachment (Ksiazek et al. 2009; 2010). Senescence also mediates the interaction of 
tumour cells and MCs via binding of α5β1 integrin to fibronectin, respectively (Ksiazek et al. 
2009). Additionally, higher production levels of TGF-β1 by MCs have been associated with 
oxidative stress, but also with age of the patients, suggesting there may be an accumulation of 
senescent MCs in vivo (Ksiazek 2013). Moreover, adhesion of ovarian cancer cells to the 
mesothelium is also mediated by MMPs (Burleson et al. 2004; Kenny et al. 2008) and their 
inhibition in ovarian cancer cells prior to inoculation in mice resulted in reduced metastasis. 
Therefore, strategies directed towards MMP inhibition would also be of interest in the treatment 
of peritoneal metastases and may prevent the accumulation of MC-derived CAFs in the 
submesothelial stroma (Egeblad and Werb 2002; Gialeli et al. 2010; Cathcart et al. 2015). 
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Recently, it has been demonstrated that invasion capacity of MCs that have undergone a 
MMT is governed, at least partially, by the VEGF/VEGF receptors/co-receptors axis. It was 
shown that blocking antibodies directed against VEGF or the co-receptor neuropilin-1 
efficiently reduced the invasion of MCs in vitro (Pérez-Lozano et al. 2013). With regard to 
VEGF, this work points to its enhanced expression as one of the most evident effects associated 
to MMT during peritoneal metastasis. Therefore, therapeutic intervention may also be directed 
at preventing peritoneal tumour vascularization via interrupting VEGF expression or its effects 
on the stromal endothelial cell (Wu et al. 2012). In fact, Sako et al. showed that peritoneal 
dissemination of gastric cancer was significantly suppressed when adenovirus expressing a 
soluble form of the VEGF receptor Flt-1 was administered intraperitoneally to mice (Sako et al. 
2004). Various anti-angiogenic therapies directed against VEGF or its receptors are presently 
being considered for the treatment of advanced abdominal cancers (Masoumi Moghaddam et al. 
2011; Gadducci et al. 2015). Particularly, the use of Bevacizumab, a monoclonal antibody 
targeting VEGF, showed an improvement of patient survival in both colorectal (Mulder et al. 
2011) and ovarian cancer (Perren et al. 2011). Additionally, tamoxifen also inhibits the invasion 
capacity of mesenchymal-like MCs via the inhibition of matrix metalloproteinase-2 (MMP-2) 
(Loureiro et al. 2013), and blocking of MMP-2 in MCs has been shown to reduce invasion by 
gastric cancer cells in vitro (Mizutani et al. 2000).  
 
In conclusion, targeting the MMT could constitute an alternative target in the treatment 
of cancers that disseminate through and metastasize in the peritoneum. Further characterization 
of the molecules involved requires development; however, analysis of the pathways that are 
differentially regulated in AFMCs could provide insight into new therapeutic options. 
Additionally, strategies that interfere with the MMT in peritoneal dialysis could be considered 
for the metastasis scenario, since the effects of MMT (MC invasion, fibroblast accumulation, 
ECM deposition and angiogenesis) in the peritoneum seem to be similar in both pathologies.  
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1. Mesothelial cells (MCs) convert into carcinoma-associated fibroblasts through a 
mesothelial-to-mesenchymal (MMT) transition induced by cancer cells. 
 
2. Adhesion to and invasion through the peritoneum is favoured by the 
mesenchymal conversion of mesothelial cells. 
 
3. MC-derived CAFs and SKOV-3 cells mutually stimulate their invasive capacity. 
 
4. Mesothelial cells in the ascitic fluid of patients with ovarian cancer have 
undergone a MMT and favour tumour progression. 
 
5. The TGF-β1-induced MMT promotes peritoneal metastasis. 
 
6. MMT in the peritoneum takes place, at least partially, via a Smad-dependent 
TGF-β1 signalling pathway. 
 
7. The TGF-β1 signalling pathway appears to be truncated in ovarian cancer cells, 
which rely on the MC-derived CAFs for transforming the pre-metastatic niche.  
 
8. Therapeutic strategies directed towards blocking and/or reversing the MMT 
could open the door to new treatments for peritoneal metastasis. !
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1. Las células mesoteliales (MCs) se convierten en fibroblastos asociados a cáncer 
(CAFs) mediante una transición mesotelio-mesénquima inducida por las células 
cancerosas. 
 
2. La conversión mesenquimal de las células mesoteliales favorece la adhesión y la 
invasión a través del peritoneo. 
 
3. Los CAFs derivados de MCs y las células SKOV-3 estimulan mutuamente su 
capacidad invasiva. 
 
4. Las MCs del líquido ascítico de pacientes con cáncer de ovario han sufrido una 
MMT y favorecen la progresión tumoral. 
 
5. La MMT inducida por TGF-β1 promueve la metástasis peritoneal. 
 
6. La MMT en el peritoneo se induce, al menos parcialmente, por la vía Smad-
dependiente de la señalización de TGF-β1. 
 
7. La vía de señalización de TGF-β1 aparece truncada en las células de cáncer 
ovario, que dependen de los CAFs derivados de MCs para transformar el nicho  
pre-metastásico 
 
8. Las estrategias terapéuticas dirigidas a bloquear o revertir la MMT podrían abrir 
la puerta a nuevos tratamientos para la metástasis peritoneal. 
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Table 1. Top 100 downregulated genes in AFMCs compared to HPMCs. 
Symbol Gene name Log Ratio p-value 
CYP17A1 Cytochrome P450, family 17, subfamily A, polypeptide 1 -11.305 1.65E-02 
SEL1L2 Sel-1 suppressor of lin-12-like 2 (C. Elegans) -8.976 5.00E-05 
SLC30A2 Solute carrier family 30 (zinc transporter), member 2 -8.666 2.02E-02 
LRP2 Low density lipoprotein receptor-related protein 2 -7.847 1.50E-04 
OVCH2 Ovochymase 2 (gene/pseudogene) -7.681 5.00E-05 
SMTNL2 Smoothelin-like 2 -7.581 9.50E-04 
NPHS1 Nephrosis 1, congenital, Finnish type (nephrin) -7.570 5.00E-05 
SPANXN1 SPANX family, member N1 -7.432 1.00E-03 
MT1G Metallothionein 1G -7.298 5.00E-05 
CAPN6 Calpain 6 -7.162 1.00E-04 
ITM2A Integral membrane protein 2A -7.072 5.00E-05 
KCNB1 Potassium channel, voltage gated Shab related subfamily B, member 1 -6.979 5.00E-05 
RGS7BP Regulator of G-protein signalling 7 binding protein -6.924 5.00E-05 
UPK3B Uroplakin 3B -6.760 5.00E-05 
ITLN1 Intelectin 1 (galactofuranose binding) -6.675 3.50E-04 
SPANXC  SPANX family, member C -6.644 3.17E-02 
VIPR2 Vasoactive intestinal peptide receptor 2 -6.546 5.00E-05 
CPB1 Carboxypeptidase B1 (tissue) -6.525 5.00E-05 
SEPP1 Selenoprotein P, plasma, 1 -6.443 5.00E-05 
KLK5 Kallikrein-related peptidase 5 -6.367 2.00E-04 
MYCN V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog -6.338 1.00E00 
ITIH3 Inter-alpha-trypsin inhibitor heavy chain 3 -6.329 7.50E-04 
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HBE1 Hemoglobin, epsilon 1 -6.295 5.00E-05 
MT1H Metallothionein 1H -6.096 3.75E-03 
OR51B4 Olfactory receptor, family 51, subfamily B, member 4 -6.077 2.60E-02 
MYOZ2 Myozenin 2 -5.648 5.00E-05 
KLK7 Kallikrein-related peptidase 7 -5.594 2.00E-04 
KLHL31 Kelch-like family member 31 -5.564 5.00E-05 
MTUS2 Microtubule associated tumor suppressor candidate 2 -5.505 5.00E-05 
CLIC5 Chloride intracellular channel 5 -5.498 5.00E-05 
MYL7 Myosin, light chain 7, regulatory -5.478 1.15E-03 
SYNPO2L Synaptopodin 2-like -5.403 5.00E-05 
SLC27A2 Solute carrier family 27 (fatty acid transporter), member 2 -5.337 5.00E-05 
RGS5 Regulator of G-protein signalling 5 -5.321 5.00E-05 
KCNA4 Potassium channel, voltage gated shaker related subfamily A, member 4 -5.314 5.00E-05 
IGFL2 IGF-like family member 2 -5.235 5.00E-05 
FGF9 Fibroblast growth factor 9 -5.220 1.90E-03 
NPR3 Natriuretic peptide receptor 3 -5.202 5.00E-05 
FLT3 Fms-related tyrosine kinase 3 -5.178 1.00E00 
ILDR2 Immunoglobulin-like domain containing receptor 2 -5.172 5.00E-05 
SFTPD Surfactant protein D -5.172 5.00E-05 
SERTM1 Serine-rich and transmembrane domain containing 1 -5.155 5.00E-05 
SERPINE3 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 3 -5.116 5.00E-05 
HPD 4-hydroxyphenylpyruvate dioxygenase -5.061 5.00E-05 
MRVI1 Murine retrovirus integration site 1 homolog -5.050 5.00E-05 
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CLSTN2 Calsyntenin 2 -5.047 5.00E-05 
THBD Thrombomodulin -5.038 5.00E-05 
TUBB4A Tubulin, beta 4A class iva -5.010 5.00E-05 
PRG4 Proteoglycan 4 -4.970 4.50E-04 
IGFL3 IGF-like family member 3 -4.958 1.20E-03 
SBK2 SH3 domain binding kinase family, member 2 -4.917 9.70E-03 
CGN Cingulin -4.891 5.00E-05 
WNT2B Wingless-type MMTV integration site family, member 2B -4.889 5.00E-05 
HBD Hemoglobin, delta -4.884 2.99E-02 
SMPD3 Sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) -4.841 5.00E-05 
HSD3B1 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 -4.840 6.50E-03 
CNGB1 Cyclic nucleotide gated channel beta 1 -4.838 5.00E-05 
ERICH5 Glutamate-rich 5 -4.832 5.00E-05 
KLK11 Kallikrein-related peptidase 11 -4.809 5.00E-05 
ALOX15 Arachidonate 15-lipoxygenase -4.798 1.35E-01 
NOX1 NADPH oxidase 1 -4.792 5.00E-05 
PTPRZ1 Protein tyrosine phosphatase, receptor-type, Z polypeptide 1 -4.787 5.00E-05 
ZFP42 ZFP42 zinc finger protein -4.783 5.00E-04 
RSPO1 R-spondin 1 -4.770 5.00E-04 
GKN1 Gastrokine 1 -4.754 9.50E-04 
PODXL Podocalyxin-like -4.752 5.00E-05 
LAMB4 Laminin, beta 4 -4.743 5.50E-04 
ANKRD2 Ankyrin repeat domain 2 (stretch responsive muscle) -4.704 5.00E-05 
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MYOZ1 Myozenin 1 -4.692 2.15E-03 
MGAT4C MGAT4 family, member C -4.606 5.00E-05 
PIP5K1B Phosphatidylinositol-4-phosphate 5-kinase, type I, beta -4.593 5.00E-05 
NRK Nik related kinase -4.578 5.00E-05 
MAOB Monoamine oxidase B -4.569 5.00E-05 
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 -4.565 5.00E-05 
CST6 Cystatin E/M -4.536 5.00E-05 
CNTN5 Contactin 5 -4.515 5.00E-05 
MUC19 Mucin 19, oligomeric -4.461 6.75E-03 
CD244 CD244 molecule, natural killer cell receptor 2B4 -4.455 4.50E-04 
CTNNA2 Catenin (cadherin-associated protein), alpha 2 -4.453 5.00E-05 
CPA4 Carboxypeptidase A4 -4.410 5.00E-05 
HOGA1 4-hydroxy-2-oxoglutarate aldolase 1 -4.407 5.00E-05 
CLDN15 Claudin 15 -4.386 5.00E-05 
ITGA7 Integrin, alpha 7 -4.386 5.00E-05 
KCNK2 Potassium channel, two pore domain subfamily K, member 2 -4.379 5.00E-05 
SBSPON Somatomedin B and thrombospondin, type 1 domain containing -4.350 5.00E-05 
PKHD1L1 Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 -4.317 5.00E-05 
MT1F Metallothionein 1F -4.300 5.00E-05 
VTN Vitronectin -4.268 5.00E-05 
CALB2 Calbindin 2 -4.266 5.00E-05 
CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 -4.263 8.50E-04 
PSG9 Pregnancy specific beta-1-glycoprotein 9 -4.223 5.00E-05 
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SLPI Secretory leukocyte peptidase inhibitor -4.212 5.00E-05 
REEP1 Receptor accessory protein 1 -4.200 5.00E-05 
ISM2 Isthmin 2 -4.175 5.00E-05 
HHIP Hedgehog interacting protein -4.124 5.00E-05 
RAB17 RAB17, member RAS oncogene family -4.120 5.00E-05 
RAET1E Retinoic acid early transcript 1E -4.110 5.00E-05 
EXTL1 Exostosin-like glycosyltransferase 1 -4.092 1.05E-03 
FRY Furry homolog (Drosophila) -4.069 5.00E-05 
DLGAP2 Discs, large (Drosophila) homolog-associated protein 2 -4.055 5.00E-05 !!  
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Table 2. Top 100 upregulated genes in AFMCs compared to HPMCs. 
Symbol Gene name Log Ratio p-value 
MMP1 Matrix metallopeptidase 1 12.37 1.03E-01 
SIGLEC1 Sialic acid binding Ig-like lectin 1, sialoadhesin 11.12 2.51E-01 
MMP3 Matrix metallopeptidase 3 10.30 7.00E-03 
HAMP Hepcidin antimicrobial peptide 10.20 2.45E-01 
HK3 Hexokinase 3 (white cell) 9.67 5.00E-05 
KLHDC7B Kelch domain containing 7B 9.63 2.75E-03 
EHF Ets homologous factor 9.60 2.29E-01 
CSF3 Colony stimulating factor 3 (granulocyte) 9.41 3.40E-02 
ESM1 Endothelial cell-specific molecule 1 9.30 1.65E-03 
FPR3 Formyl peptide receptor 3 9.27 7.50E-04 
CCL4L1/CCL4L2 Chemokine (C-C motif) ligand 4-like 1 8.97 5.00E-05 
EGR3 Early growth response 3 8.94 1.00E-04 
STAB1 Stabilin 1 8.90 5.00E-05 
TREM1 Triggering receptor expressed on myeloid cells 1 8.89 1.34E-02 
NGEF Neuronal guanine nucleotide exchange factor 8.77 5.00E-05 
NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 8.74 5.00E-05 
SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 8.70 4.11E-02 
SPP1 Secreted phosphoprotein 1 8.64 9.50E-04 
CXCL8 Chemokine (C-X-C motif) ligand 8 8.57 5.00E-05 
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 8.56 8.00E-04 
IL33 Interleukin 33 8.51 5.00E-05 
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 8.46 5.00E-05 
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MME Membrane metallo-endopeptidase 8.45 5.00E-05 
IFI44L Interferon-induced protein 44-like 8.25 5.00E-05 
G0S2 G0/G1 switch 2 8.20 5.10E-03 
CXCL3 Chemokine (C-X-C motif) ligand 3 8.10 1.10E-03 
IL1B Interleukin 1, beta 8.09 5.00E-05 
NTM Neurotrimin 8.08 5.45E-03 
WNT7A Wingless-type MMTV integration site family, member 7A 8.06 1.00E+00 
SPI1 Spi-1 proto-oncogene 8.04 8.82E-02 
SLC11A1 Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1 8.02 9.50E-04 
HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 8.01 5.00E-05 
TNF Tumor necrosis factor 7.97 4.50E-04 
LILRB2 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2 7.92 5.00E-05 
TSLP Thymic stromal lymphopoietin 7.92 2.00E-04 
MMP9 Matrix metallopeptidase 9 7.91 1.80E-03 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 7.90 1.18E-02 
PTX3 Pentraxin 3, long 7.82 5.00E-05 
MSR1 Macrophage scavenger receptor 1 7.78 9.59E-02 
TREM2 Triggering receptor expressed on myeloid cells 2 7.71 2.42E-01 
HSPA7 Heat shock 70kda protein 7 (HSP70B) 7.61 1.37E-02 
KMO Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 7.61 5.00E-05 
LILRA6 Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 6 7.59 5.40E-03 
LYZ Lysozyme 7.59 5.00E-05 
CLEC7A C-type lectin domain family 7, member A 7.56 5.60E-03 
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CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 7.39 5.00E-05 
LILRB4 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 7.33 2.31E-01 
GPR183 G protein-coupled receptor 183 7.31 4.84E-02 
GNA15 Guanine nucleotide binding protein (G protein), alpha 15 (Gq class) 7.27 1.00E+00 
KYNU Kynureninase 7.26 5.00E-05 
LILRB5 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5 7.25 8.40E-03 
FOLR1 Folate receptor 1 (adult) 7.21 2.39E-01 
MMP7 Matrix metallopeptidase 7 7.20 1.40E-01 
PTGER2 Prostaglandin E receptor 2 (subtype EP2), 53kda 7.20 1.00E+00 
PTPRC Protein tyrosine phosphatase, receptor type, C 7.19 6.45E-03 
COL6A3 Collagen, type VI, alpha 3 7.09 5.00E-05 
CCL3L3 Chemokine (C-C motif) ligand 3-like 3 7.05 5.00E-05 
TNFRSF6B Tumor necrosis factor receptor superfamily, member 6b, decoy 7.03 1.00E+00 
RSAD2 Radical S-adenosyl methionine domain containing 2 7.01 5.00E-05 
SYK Spleen tyrosine kinase 6.95 6.09E-02 
GLI1 GLI family zinc finger 1 6.90 6.00E-04 
CXCL2 Chemokine (C-X-C motif) ligand 2 6.86 5.00E-05 
FCGR3A/FCGR3B Fc fragment of igg, low affinity iiia, receptor (CD16a) 6.82 1.00E+00 
CXCR4 Chemokine (C-X-C motif) receptor 4 6.75 2.19E-01 
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 6.74 1.00E+00 
HAS2 Hyaluronan synthase 2 6.74 2.09E-01 
SOX17 SRY (sex determining region Y)-box 17 6.71 5.80E-03 
NCF4 Neutrophil cytosolic factor 4, 40kda 6.70 1.88E-01 
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CXCL5 Chemokine (C-X-C motif) ligand 5 6.63 5.00E-05 
SLC44A4 Solute carrier family 44, member 4 6.60 1.12E-02 
GBP5 Guanylate binding protein 5 6.58 6.80E-03 
ANXA10 Annexin A10 6.58 5.00E-05 
INHBE Inhibin, beta E 6.56 5.00E-05 
FCER1G Fc fragment of ige, high affinity I, receptor for; gamma polypeptide 6.56 5.16E-02 
SLA Src-like-adaptor 6.51 5.00E-05 
SLC7A11 Solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 6.51 5.00E-05 
EGR1 Early growth response 1 6.46 5.00E-05 
FIBIN Fin bud initiation factor homolog (zebrafish) 6.37 9.80E-03 
IL13RA2 Interleukin 13 receptor, alpha 2 6.37 5.00E-05 
CTHRC1 Collagen triple helix repeat containing 1 6.36 5.00E-05 
ADM2 Adrenomedullin 2 6.36 5.00E-05 
UCN2 Urocortin 2 6.35 1.00E+00 
IRF8 Interferon regulatory factor 8 6.34 1.01E-01 
PHLDA1 Pleckstrin homology-like domain, family A, member 1 6.30 5.00E-05 
PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 6.30 5.00E-05 
XDH Xanthine dehydrogenase 6.29 1.00E+00 
HIF3A Hypoxia inducible factor 3, alpha subunit 6.24 1.00E+00 
FOSB FBJ murine osteosarcoma viral oncogene homolog B 6.22 5.00E-05 
KLRC4-
KLRK1/KLRK1 Killer cell lectin-like receptor subfamily K, member 1 6.19 1.00E+00 
CD52 CD52 molecule 6.18 1.56E-02 
RGCC Regulator of cell cycle 6.18 2.41E-01 
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CD69 CD69 molecule 6.17 1.00E+00 
SLAMF8 SLAM family member 8 6.17 5.00E-05 
FOXC2 Forkhead box C2 6.17 1.00E+00 
ITGA11 Integrin, alpha 11 6.12 5.00E-05 
RPLP0P2 Ribosomal protein, large, P0 pseudogene 2 6.12 5.00E-05 
EPCAM Epithelial cell adhesion molecule 6.04 5.00E-05 
C15orf48 Chromosome 15 open reading frame 48 6.00 5.00E-05 
KLF2 Kruppel-like factor 2 5.99 5.00E-05 
C5AR1 Complement component 5a receptor 1 5.97 3.35E-03 
